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Adenosine signalling has been implicated in the pathophysiology of CNS disorders, such as 
stroke, epilepsy and Parkinson’s disease (PD).  Recent reports suggest that prolonged activation 
of adenosine A1 and A2A receptors during stroke increases hippocampal neurodegeneration. 
Epidemiological studies suggested that the anti-diabetic drug metformin could promote 
neuroprotection in stroke patients, but the precise mechanism of this neuroprotective property 
remains unclear, and current literature was often conflicting. Based on pilot studies carried out 
initially in ex vivo rat hippocampal brain slices, we investigated our hypothesis that metformin 
binds to adenosine receptors to mediate neuroprotection. Using in vivo administration of 
adenosine A1 receptor agonist N(6)cyclopentyladenosine (CPA), with or without the A1R 
antagonist dipropylcyclopentylxanthine (DPCPX), and elevation of endogenous adenosine in 
our ex-vivo hypoxia-reperfusion model, we aimed to characterize the effects of metformin co-
treatments on the electrophysiological, biochemical, and morphological changes in rat 
hippocampus and correlated these with behavioral outcomes. Results indicated that metformin 
treatments prevented synaptic depression induced by CPA administration or hypoxia 
treatments. Moreover, metformin reduced adenosine A1 receptor-mediated hippocampal 
neurodegeneration and behavioral deficits. Finally, radioligand binding studies revealed a 
potential binding affinity of metformin to A1Rs from hippocampal membranes. In conclusion, 
the clinically approved metformin was effective in preventing A1R-mediated hippocampal 
neuronal damage, synaptic depression and accompanying behavioral abnormalities.  
Metformin, with partial binding affinity to at least the A1R, exhibits neuroprotective properties 
by acting to antagonize the effects of endogenous adenosine during ischemic conditions. This 
study provides support that chronic A1R stimulation promotes neurodegeneration and 
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1.1  Stroke 
1.1.1  Stroke Pathology 
In Canada, stroke is the third leading cause of death according to the Heart and Stroke 
Association (Jolly, Whelan, & Davy, 2018). Stroke causes cognitive problems, mood disorders, 
anxiety, and motor deficits (Jolly et al., 2018; Murphy & Corbett, 2009), and is the leading 
cause of disability in Canada (Jolly et al., 2018). 
There are two different types of stroke, ischemic and hemorrhagic stroke, both having different 
pathophysiologies, phenotypes, symptoms, and after-effects. Ischemic stroke is defined as a 
loss of oxygen supply to the surrounding tissues (Hanna, 2009). A cerebral vessel becomes 
blocked by a clot,  resulting in neuronal cells being starved of oxygen and later entering a 
“distressed” physiological state (e.g., oxidative and nitrosative stress and pro-inflammatory 
reactions) (Amantea, Nappi, Bernardi, Bagetta, & Corasaniti, 2009).  This ultimately leads to 
increased apoptotic and overall cell death in the surrounding brain areas (George & Steinberg, 
2015). These tissues are deprived not only of oxygen but also of blood supply containing many 
macro- and micronutrients crucial for their overall cellular functioning and homeostasis 
activities. 
Hemorrhagic stroke following vessel rupture is similar in effect but results from a loss of 
controlled reperfusion within the brain. This leads to an increase in intracranial pressure 
causing damage to the adjacent and surrounding tissues (Lefkovits et al., 1992). Hypertension, 
high cholesterol levels, smoking, diabetes, as well as clotting factor disorders and pathologies 
are risk factors for the incidence of hemorrhagic stroke (Grysiewicz, Thomas, & Pandey, 2008).  
These risk factors promote the vasculature wall break down and collagen replacement, which 
results in a decrease in compliance of the vessels increasing their susceptibility to rupture 
(Testai & Aiyagari, 2008). 
Ischemic stroke, on the other hand, most commonly takes place in branching small to 
intermediate cerebral vessels, where the pressure and velocity of blood flow increases as the 
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size of the vessel decreases. Clots which form in the larger vessels of the vasculature, later 
detach and subsequently become lodged in the smaller vessels, causing a stroke to occur. ‘Mini-
strokes’ termed as transient ischemic attacks (TIAs) happen frequently in individuals with one 
or more of the following conditions: hypertension, type II diabetes, cardiovascular disease, 
have poor diet, obese or are smokers (Grysiewicz et al., 2008). So, while these TIAs happen 
very rapidly, and often resolve themselves in under an hour (Albers et al., 2002) with cognitive 
deficits lasting 24 hours or less (Grysiewicz et al., 2008) and the sufferer noticing no significant 
changes or disruptions in cognition, TIAs are important predictors of stroke (Johnston, Gress, 
Browner, & Sidney, 2000). Studies suggest that 8-10% of TIA sufferers go on to develop stroke 
within 90 days of TIA with half of these individuals having strokes within the first 7 days 
(Rothwell & Warlow, 2005; Wolf et al., 1992), and almost 30% within 5 years (Wolf et al., 
1992). 
1.1.2  Stroke Interventions 
Ischemic stroke therapy consists of the immediate administration of recombinant tissue 
plasminogen activator (r-tPA) or aspirin within the first 3 to 4.5 hours of stroke onset to resolve 
any blockages depriving the tissues of oxygen (Hacke et al., 2008). This helps to limit the time 
the tissues were kept under anoxic conditions (George & Steinberg, 2015). However, it was 
also noted that fewer than 2% of stroke patients receive this treatment as a result of delays in 
stroke diagnoses and subsequent late admissions to stroke centres (Hacke et al., 2008). R-tPA 
treatment also does not address the secondary concern of increased immune cell infiltration to 
the infarct zone and penumbra following stroke (Amantea et al., 2009; Walz & Cayabyab, 
2017). 
Hemorrhagic stroke therapy consists of surgical intervention for major bleeds or the 
administration of IV fluids and medications for minor bleeds (Dorsch, 1997). Hemorrhagic 
stroke only makes up 10% of all stroke cases while ischemic stroke makes up 90% of all stroke 
cases (Grysiewicz et al., 2008).  
Therefore, most preclinical stroke research focuses on understanding ischemic stroke 
pathophysiology, and intracellular post-stroke signalling mechanisms to elucidate novel 
therapeutic targets. This includes investigating receptors, proteins, and downstream signalling 
molecules that change in structure, function, and quantity during stroke.  
3 
 
Previous studies have identified adenosine as a neuromodulator of interest during hypoxic and 
ischemic conditions (Nieber, Eschke, & Brand, 1999; Rudolphi, Schubert, Parkinson, & 
Fredholm, 1992), but the specific role of adenosine in post-stroke pathophysiology is currently 
under investigation in our lab (Z. Chen et al., 2014; Stockwell, Chen, Niazi, Nosib, & 
Cayabyab, 2016; Stockwell, Jakova, & Cayabyab, 2017) 
1.2  Adenosine  
1.2.1  Adenosine Signalling  
Adenosine is a ubiquitous neuromodulator which mediates and modulates cell signalling 
(Borea, Varani, Gessi, Merighi, & Vincenzi, 2018). It can act as an intermediate at both 
presynaptic and postsynaptic nerve terminals to affect synaptic transmission and synapse 
responses (Chu et al., 2013). However, like an autocrine factor, its effects are often transient 
and short lived in action (A. Briones, 2014). With a half-life of less than ten seconds (Klabunde, 
1983), and differing affinities for each of its four receptor subtypes (Dunwiddie & Masino, 
2001), adenosine signalling rapidly becomes both complex and varied in action.  
1.2.2  Adenosine Cycling 
At rest, extracellular concentrations of adenosine range between 30-300nM (Borea et al., 2018; 
Dunwiddie & Masino, 2001) and intracellular adenosine concentrations remain stable at 
approximately 50nM (Bradley, Harris, & Jenner, 2005).   
However, following ischemia, hypoxia, trauma, inflammation, oxidative and nitrosative stress 
(Haskó, Linden, Cronstein, & Pacher, 2008), seizures, pain, diabetes, cancer (Borea et al., 
2018), metabolic poisoning and field stimulation of brain slices, there is an imbalance between 
energy supply and energy demand. This leads to the increase of extracellular adenosine levels 
via different pathways and mechanisms depending on the presenting stimuli (Bradley et al., 
2005). 
Adenosine triphosphate (ATP) can be moved out of the cell using connexin channels and anion 
transport channels or via vesicular transport. This extracellular ATP can then be converted to 
adenosine via an ecto-nucleoside triphosphate diphosphohydrolase enzyme. Or alternatively 
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intracellular ATP can be converted within the cell to adenosine via 5’-nucleotidase, and then 
moved out of the cell via an equilibrative bidirectional nucleoside transporter (Bradley et al., 
2005).  
Either of these listed pathways will cause massive increases in extracellular adenosine levels, 
and are thought to occur at nerve terminals and also in surrounding non-neuronal cells like 
astrocytes and dendritic cells. However, although the equilibrative nucleoside transporters are 
widely believed to be major players in controlling extracellular adenosine levels both at 
baseline and in pathophysiological conditions, such as stroke, or seizures (Baldwin et al., 
2004), concentrative nucleoside transporters are not involved in extracellular adenosine 
increase. These concentrative transporters are only able to move nucleosides with sodium ions 
into the cell from the extracellular space (Pastor-Anglada & Pérez-Torras, 2018).   
At low extracellular adenosine levels, adenosine is cleared by adenosine kinase which converts 
adenosine to adenosine monophosphate (AMP). Inhibitors of this enzyme have been shown to 
cause increases in extracellular adenosine under normal physiological conditions (Lloyd & 
Fredholm, 1995; Sciotti & Van Wylen, 1993). At high extracellular adenosine levels, adenosine 
is not cleared by adenosine kinase, instead adenosine deaminase was found to play a pivotal 
role by converting adenosine into inosine. Inhibitors of this enzyme during times of metabolic 
insult showed increases in extracellular adenosine (Rochon, Rousse, & Robitaille, 2001). 
As ATP levels are usually 100,000 times greater than adenosine levels we can therefore observe 
significant changes in adenosine levels without observing major changes in ATP levels 
(Bradley et al., 2005). However, during stroke there is a 100-fold post-stroke elevation of 
extracellular adenosine (Bertil B Fredholm, Irenius, Kull, & Schulte, 2001), and this 
supraphysiological adenosine level remains significantly elevated for several weeks.   
1.2.3  Adenosine and its Receptors 
With an increased availability of adenosine to bind to its receptors, it becomes increasingly 
important to look at the function of each adenosine receptor subtype and how its activation is 
implicated in stroke pathophysiology.   
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There are four known subtypes of adenosine receptor: A1, A2A, A2B and A3. These receptor 
subtypes are coupled to G-proteins which can be inhibitory (αi) or excitatory (αs) in action. An 
inhibitory response leads to the inhibition of adenylyl cyclase which decreases cell signalling, 
while an excitatory response leads to the activation of adenylyl cyclase causing an increase in 
cell signalling (Borea et al., 2018; B B Fredholm, IJzerman, Jacobson, Klotz, & Linden, 2001; 
Olah & Stiles, 1995). 
Of these four subtypes of adenosine receptor, the adenosine A1 and A3 receptors are inhibitory 
in function, while adenosine A2A and A2B receptors are excitatory in function (Stockwell et 
al., 2017). Knowing that there are various distributions of adenosine receptor throughout the 
body, where A1 and A2A are more predominantly expressed over the A2B and A3 receptors; 
this tells us that adenosine-receptor binding can mediate a range of different functions 
depending, firstly, on the concentration of adenosine present, and secondly, on the distribution 
and density of adenosine receptor subtypes available.  
1.2.4  Adenosine and the Brain 
The hippocampus is the region of the brain involved in memory, learning, thought and higher 
cognitive processes (Genon, Reid, Langner, Amunts, & Eickhoff, 2018). It is implicated in 
stroke pathophysiology because smaller hippocampal volume is associated with brain infarcts 
and poorer memory (Blum et al., 2012). The understanding is that this breakdown is attributed 
to the unregulated transfer of molecules across the membranes (Haley & Lawrence, 2017). 
Additionally, a recent study in humans showed that there is an age-related breakdown of the 
blood brain barrier that begins in the hippocampus, and this was found to be correlated with 
worsening cognitive impairment (Montagne et al., 2015; Nation et al., 2019). This observation 
coupled with the knowledge that there are greater numbers of adenosine receptors within the 
hippocampus as compared to other structures of the brain (Soliman, Fathalla, & Moustafa, 
2018), this can result in a wide range of adenosine-mediated responses during stress and makes 
the hippocampus a brain region of intense interest in stroke pathology.  
1.2.5  Adenosine Increase and Ischemia  
Under ischemic conditions there is increased metabolic stress as a result of oxygen and glucose 
deprivation to the tissues (Kim, Kim, Kwon, Park, & Chung, 2006). These conditions cause 
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subsequent changes in AMP/ATP ratio, with bias towards AMP and adenosine production 
(Beauloye et al., 2001). At rest under normal physiological conditions, basal ATP 
concentration is in the millimolar range with basal adenosine concentration in the nanomolar 
range (Chu et al., 2013). Therefore, it is not difficult to understand how small changes in ATP 
levels can significantly alter adenosine homeostasis (Bradley et al., 2005). 
However now that we have addressed the problem of normal physiological adenosine increase 
and cycling and pathological adenosine increase, another important facet of adenosine 
signalling is its associated receptors. 
1.2.6  Clinical Implications of Adenosine Increase 
Adenosine is a potent agonist at adenosine A1 and A2A receptors versus adenosine A2B and 
A3 receptors (Bertil B Fredholm et al., 2001). This is because A1 and A2A receptors have the 
greatest affinity for adenosine (73nM and 150nM, respectively) and therefore sufficient tonic 
activation of these receptors is at work at low concentrations of adenosine, while A2B and A3 
receptors have the lowest affinity for adenosine (5.1μM and 6.5μM, respectively) and therefore 
would only be activated when adenosine concentrations are significantly greater than they 
would be under normal conditions (J.-F. Chen, Lee, & Chern, 2014; Bertil B. Fredholm, 1995). 
This is important because during hypoxia and ischemia in tissues with abundant adenosine A1 
receptors, such as the hippocampus, it is thought that adenosine and AMP may act as retaliatory 
metabolites; with AMP acting intracellularly via adenosine monophosphate-activated protein 
kinase (AMPK) and adenosine acting extracellularly via its A1 receptors (Chu et al., 2013).  
These adenosine A1 receptors (Goodman & Synder, 1982) are found on both pre-synaptic and 
post-synaptic sites (Deckert & Jorgensen, 1988), dendrites (Rivkees, Price, & Zhou, 1995), and 
axonal fibres (Swanson, Drazba, & Rivkees, 1995; D. K. Von Lubitz, 1999) within the 
hippocampus (Swanson et al., 1995; D. K. Von Lubitz, 1999). So whereas acute A1 receptor 
stimulation was initially thought to be neuroprotective (K A Jacobson, von Lubitz, Daly, & 
Fredholm, 1996), research has shown that chronic A1 receptor stimulation is indeed 
neurotoxic (Z. Chen et al., 2014; D. K. Von Lubitz, Lin, & Jacobson, 1995) with the 




1.2.7  Benefits of Adenosine Receptor Activation and Inactivation 
Adenosine receptor agonists and antagonists have been proposed as therapeutic agents in 
clinical trials in a wide array of conditions (Kenneth A Jacobson & Gao, 2006; Sachdeva & 
Gupta, 2013).   
Therefore, we believe that by targeting some of these receptors which are known to be 
implicated in stroke pathology, it may be possible to provide some therapeutic benefit at the 
time of stroke.  
1.3  Metformin 
1.3.1 Type II Diabetes 
Type II Diabetes (T2D) is a disease which is defined as a combination of hyperglycaemia and 
insulin resistance. Where normal blood glucose levels range from 4-6mmol L-1, levels above 
this range can be an indication of the beginnings of prediabetic pathology.  
1.3.2 Antidiabetics and Disease 
There are 8 different classes of antidiabetic drugs, these are: biguanides, sulfonylureas, 
dipeptidyl peptidase (DPP) IV inhibitors, glucagon-like peptide (GLP) 1 agonists, alpha-
glucosidase inhibitors, meglitinides, thiazolidinediones (TZDs) and sodium-glucose co-
transporter (SGLT) 2 inhibitors. These antidiabetic drugs can be administered in combination 
or individually depending on an assessment of the patient’s current β-cell function and the 
knowledge of the physician. Other factors also taken into consideration are comorbidities, the 
potential for drug-drug interactions, and the complexity of the treatment versus compliance. 
As a final line of therapy, insulin can be given in combination with these antidiabetic drugs in 
patients with end stage or worsening diabetic conditions which can no longer be well controlled 




1.3.3 Diabetes and Disease 
T2D has been found to be a risk factor for the development and/or progression of 
neurodegeneration in epidemiological studies where data shows that the pathophysiology of 
T2D may overlap with PD and other age-related diseases (Hu, Jousilahti, Bidel, Antikainen, & 
Tuomilehto, 2007; Santiago & Potashkin, 2013).  
Thus far, studies show that anti-diabetic interventions with or without insulin are 
neuroprotective and delay diagnoses of neurodegenerative conditions by several years 
(Wahlqvist et al., 2012). Preclinical studies show biguanides, TZDs and sulfonylureas have 
neuroprotective effects against the pathogenesis of motor-related neurodegenerative conditions 
like Huntington’s (HD), Alzheimer’s disease (AD), and Parkinson’s disease (PD) in animal 
models (Ma et al., 2007; Martin et al., 2009; Wahlqvist et al., 2012), particularly in relation to 
the reduction of oxidative stress, but the specific mechanisms of action for these pathways 
currently remain unknown.  
Additionally, hyperglycemia is a problem in T2D disease pathology because it leads to the 
production of advanced glycation end products (AGEs). AGEs are formed via a nonenzymatic 
reaction involving glucose with proteins, lipids and nucleic acids (Goh & Cooper, 2008). When 
AGEs bind to the receptor for AGEs (RAGE), this leads to an increase in intracellular signalling 
which promotes increases in oxidative stress via the reduction of nitric oxide production 
(Chakravarthy, Hayes, Stitt, McAuley, & Archer, 1998).; while also contributing to the 
increase of the transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of 
activated B cells), proinflammatory cytokines like TNF-α (tumour necrosis factor-α) and IL-6 
(interleukin 6), as well as prosclerotic adhesion molecules such as ICAM-1 (intercellular 
adhesion molecule-1) and VCAM-1 (vascular cell adhesion molecule-1) along with VEGF 
(vascular endothelial growth factor) (Goh & Cooper, 2008). As a result, by controlling 
hyperglycemia via antidiabetic medications like metformin in T2D, the potential for the 
overproduction of AGEs and subsequent vascular damage is greatly reduced (Marx et al., 2004; 





1.3.4  Metformin – Neuroprotection in the Brain  
Metformin, a biguanide, is used as the first line of therapy for T2D, and is listed as an essential 
medicine by the World Health Organisation (WHO) (Knowler et al., 2002; Lu et al., 2016). It 
exerts its effect to increase the uptake of peripheral blood glucose levels via the activation of a 
molecule known as AMPK (Zhou et al., 2001). However, more recent studies now show that 
metformin inhibits hepatic gluconeogenesis in an AMPK/liver kinase B1 (LKB1) independent 
manner  to decrease blood glucose levels (Foretz et al., 2010). This inhibition is thought to be 
related to the ability of metformin to inhibit mitochondrial glycerophosphate dehydrogenase, 
the redox shuttle enzyme, which plays a role in mediating cytosolic and mitochondrial redox 
states (Madiraju et al., 2014, 2018; Miller & Birnbaum, 2010), alluding to the idea that 
metformin does appear to have a significant impact on mitochondrial function.  
However, outside of its antidiabetic effect, metformin has also been shown to confer 
therapeutic benefits for diseases such as polycystic ovary syndrome (Tang, Glanville, Orsi, 
Barth, & Balen, 2006), cancer (Duncan & Schmidt, 2009; Salani et al., 2014), and 
atherosclerosis (Mamputu, Wiernsperger, & Renier, 2003), all through different mechanisms 
of action.  
In addition, recent preclinical studies also suggest that metformin can confer neuroprotection 
in the middle cerebral artery occlusion (MCAO) stroke model. Chronic metformin 
administration prior to stroke is thought to confer neuroprotection in the MCAO model by 
preventing ischemic brain injury while inducing angiogenesis (Venna, Li, Hammond, Mancini, 
& McCullough, 2014) and neurogenesis (Liu, Tang, Zhang, Wang, & Yang, 2014). Metformin 
treatment was also implicated in enhancing spatial memory formation in another study (J. 
Wang et al., 2012). 
On the other hand, caution should be used when considering metformin as a potential novel 
drug for treating ischemic events. While many studies suggest that metformin has substantial 
neuroprotective potential, the effect of metformin in different animal models of stroke remains 
controversial.   
In a study where metformin was administered acutely (3 days) prior to stroke, it was shown to 
exacerbate stroke damage and increase infarct size, while metformin administered chronically 
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(3 weeks) pre-stroke showed neuroprotective effects dependent on nitric oxide (Li, Benashski, 
Venna, & McCullough, 2010). This is thought to be in relation to the action of metformin to 
inhibit the production of reactive oxygen species (ROS) via its effect on mitochondrial redox 
processes (Lu et al., 2016; Owen, Doran, & Halestrap, 2000). 
On the other hand, another study showed that the acute administration of metformin in an in 
vivo MCAO stroke model was neuroprotective. In this publication, researchers found that the 
activation of AMPK induced autophagy in the brain, reduced infarct volume, decreased cell 
apoptosis and augmented subsequent neurological deficits (T. Jiang et al., 2014). These 
beneficial effects were completely reversed when compound C, the AMPK inhibitor, was 
utilised and partially reversed when 3-methyladenine, the autophagy inhibitor, was utilised. 
This study highlighted the benefit of preconditioning the tissues with metformin prior to the 
induction of the stroke (T. Jiang et al., 2014). This was in contrast to prior findings by Li and 
colleagues (Li et al., 2010) where the effect of acute metformin administration during MCAO 
was neurotoxic and exacerbated stroke damage. 
Due to the challenges in the literature in deciphering the differences in mode of administration 
of metformin treatment, as well as significant differences in the concentrations and doses used; 
the overall mechanism of metformin’s neuroprotective potential in the brain has not yet been 
discussed in depth, and studies often seem to provide conflicting results that favour either 
degeneration or protection.  
Additionally, within these studies there are also varying degrees of ischemic insult, various 
time durations and different stroke models that are being used to replicate in vivo strokes in 
patients. Therefore, while AMPK and/or metformin may prove to be neuroprotective in some 
studies, in others it is noted to be neurotoxic. Overall, it becomes extremely difficult to interpret 
these studies and to decipher the tipping point between metformin’s deleterious and beneficial 
effects.  
Another pathway of note in ischemic studies looks at the relationship between adenosine and 
glutamate. Both glutamate and adenosine increase during global ischemia, and studies using 
global ischemia models suggest that endogenous adenosine, as well as exogenous adenosine 
and selective A1R agonists, when acutely administered, provide neuroprotection primarily by 
inhibiting glutamate excitotoxicity (Dunwiddie & Masino, 2001).  Given that the exogenous 
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administration of adenosine or selective adenosine A1 receptor agonists have different effects 
in stroke damage (enhancing neurotoxicity when applied chronically (D. K. Von Lubitz et al., 
1994) or neuroprotection when applied acutely (K A Jacobson et al., 1996)), it is plausible to 
consider that the controversy surrounding metformin’s effects in stroke model may be related 
to its potential interaction with adenosine signalling.  To date, there are no studies linking the 
potential actions of metformin on adenosine-related proteins that may play an important role 
in neuroprotection or enhancing neurotoxicity.  However, some studies have mentioned 5’ 
adenosine monophosphate-activated protein kinase (AMPK) as a compound of interest in 
metformin-related studies.  
1.3.5  5’ Adenosine monophosphate-activated protein kinase (AMPK) 
At this point in this thesis, it is important to highlight the role of AMPK, how it is implicated 
in facilitating neuroprotection, and to also answer the question of whether metformin exerts its 
neuroprotective effects via AMPK.  
It has been found that an increase in AMP leads to the activation of AMPK which is comprised 
of α, β, and γ subunits (Carling, Thornton, Woods, & Sanders, 2012). The γ subunit senses the 
change in AMP/ATP ratio, which is an indicator of cellular energy levels and metabolic stress 
(Li & McCullough, 2010). Increases in AMPK activity has been noted to be responsible for 
improving oxidative stress (Blázquez, Woods, de Ceballos, Carling, & Guzmán, 1999), 
autophagy (T. Jiang et al., 2015; Manwani & McCullough, 2013; Sheng et al., 2010), apoptosis 
(Duan et al., 2016; T. Jiang et al., 2015), mitochondrial dysfunction (Toyama et al., 2016), 
glutamate excitotoxicity (Connolly, Düssmann, Anilkumar, Huber, & Prehn, 2014), 
neuroinflammation (Liu, Tang, Li, et al., 2014), angiogenesis (Jin et al., 2014), neurological 
score improvements and the amelioration of behavioral deficits (Ashabi et al., 2017; 
Ghadernezhad, Khalaj, Pazoki-Toroudi, Mirmasoumi, & Ashabi, 2016; Sarkaki et al., 2015).  
Several neuroprotective benefits of AMPK have also been listed in the literature to be induced 
by the chronic administration of metformin prior to stroke (Jia, Cheng, Ni, & Zhen, 2015; Li 
et al., 2010). Similarly, as with metformin studies where some show neuroprotective benefits 
and others show neurotoxic effects, the same can be seen with AMPK-related studies. 
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Inhibitors of AMPK like compound C have been found to inhibit or disrupt the neuroprotective 
potential of AMPK during oxygen-glucose deprivation studies, which model ischemia in vitro 
(P. Wang et al., 2011).  In contrast, AMPK activators like AICAR have been shown to facilitate 
neuroprotection in the same model (Culmsee, Monnig, Kemp, & Mattson, 2001; S. Jiang et al., 
2018). 
There also are some reports in the literature which suggest that metformin may exert some 
effects that are independent of AMPK, which therefore would directly contradict the idea that 
metformin is a direct activator of AMPK (Kalender et al., 2010; Rena, Pearson, & Sakamoto, 
2013). This tells us that if metformin is not a direct activator of AMPK then its effects are not 
synonymous with AMPK studies, and it again becomes increasingly difficult to tease out 
metformin-dependent effects from AMPK-mediated effects. Many stroke-related studies that 
reported post-stroke neuroprotective effects with metformin or AMPK either did not test 
AMPK levels or failed to utilise AMPK inhibitors like Compound C in their experimental 
designs.  
Overall it seems that the post-ischemic effect of metformin is dependent on three factors: 
duration of stroke, concentration of metformin used and duration of administration. 
Given the scope of the beneficial yet controversial effects of metformin/AMPK during stroke, 
our study will primarily focus on understanding the effect of metformin in response to 
supraphysiological adenosine increases ex-vivo and in vivo.  
1.4  Rationale 
Firstly, we want to test whether acute or chronic A1R stimulation at the proposed 
concentrations mimics the adenosine elevation that occurs during stroke resulting in neuronal 
dysfunction and cell death. We will be using acute one-hour metformin incubations of 
hippocampal brain slices ex vivo or intraperitoneal (i.p.) injections of metformin in vivo thirty 
minutes prior to administration of adenosine A1 receptor agonist (CPA) to test whether 
hippocampal neurodegeneration and synaptic depression can be prevented by metformin; and 
whether this effect is neuroprotective and is accompanied by the attenuation of both cognitive 
and motor deficits in a rat animal model. We will also test the hypothesis that the anti-diabetic 
drug metformin interferes with adenosine A1R signalling, thereby promoting neuroprotection 
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by blocking CPA-induced effects. The following are brief outlines of my experimental 
objectives and the overall hypothesis of my project. 
1.5  Hypothesis 
Given that the anti-diabetic drug metformin has been implicated in modulating responses to 
stroke-induced brain damage, we hypothesize that metformin, when given immediately before 
or after a stroke, reduces neurodegeneration in rat hippocampus by disrupting adenosine A1 
receptor (A1R) signalling.   
1.6  Objectives 
 
• To understand the effect of varying concentrations of metformin in vivo and ex vivo on 
stroke-like insults.  
• To characterise the effects of metformin on hippocampal neuron health exposed to 
chronic A1R signalling. 
• To investigate the effect of metformin on adenosine A1R signalling in vivo and ex vivo.  
 
1.7  Clinical Relevance 
With stroke being a multi-faceted disease with so many different cell types and receptors being 
implicated in stroke-related cell death and injury, it is important to target as many of these 
pathways to provide the best possible outcome for the patient.  My study presents the first 
evidence for the potential binding activity of metformin on adenosine receptors, specifically 
A1Rs. Therefore, with a drug such as metformin which operates via many different 
mechanisms of action, we believe it could be repurposed as an inhibitor of adenosine signalling 
and as a secondary line of therapy to be given concurrently with r-tPA to extend the therapeutic 
window. Alternatively, metformin could also be administered pre-stroke to patients at high risk 
for the development of ischemic strokes as a preventative measure.  
Given that the literature notes other mechanisms of action for metformin including increasing 
angiogenesis, neurogenesis, anti-inflammatory effects via microglia activation, reductions in 
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oxidative stress via increases in nitric oxide synthesis, anti-cancer effects via mTOR activation, 
increases in PP2A activity in AD, a decrease in tau phosphorylation and the reduction of 
huntingtin protein load in HD, it is possible that beyond stroke metformin could be beneficial 


















2. MATERIALS AND METHODS 
2.1  Ethics Statement 
All animal care and experimental procedures were carried out in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH publications no. 
85-23, revised 1985) and according to guidelines of the Canadian Council for Animal Care 
(CCAC) under the supervision of the University of Saskatchewan Committee on Animal Care 
and Supply (under animal protocol 20070090). All experimental designs and protocols were in 
accordance with ARRIVE guidelines to minimize animal suffering and the number of animals 
used in the study (Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010; Stockwell et al., 
2016). 
2.2  Animal Model 
Male Sprague Dawley rats purchased from Charles River, Montreal, Quebec, Canada were 
housed initially with their mother in cages of 16 until postnatal day 21; after day 21 they were 
housed in cages of 4 and later in cages of 2. Animal housing cages were changed every 2-3 
days, the temperature was maintained at 20-24 degrees Celsius, with a natural 12h light-dark 
cycle from 7am-7pm (light) and 7pm-7am (dark). All animals had unlimited access to food 
pellets and water.  
2.3  Live Hippocampal Slice Preparation 
Male Sprague Dawley rats postnatal day 28-35 (Charles River, Canada) were anaesthetized 
with halothane (2-bromo-2-chloro-1,1,1-trifluoroethane Sigma-Aldrich), and decapitated. The 
brains were immediately removed and submerged in oxygenated, ice-cold high-sucrose 
dissection medium containing 87mM NaCl, 25mM NaHCO3, 25mM glucose, 75mM sucrose, 
2.5mM KCl, 1.25mM NaH2PO4, 7.0mM MgCl2 and 500μM CaCl2 (Brust et al., 2007). 
Hippocampal slices were taken at 400μm thickness using a vibrating tissue slicer (VTS1200S, 
Vibram Instruments, Germany), and slicing was performed in the same ice-cold oxygenated 
dissection medium as above. Slices were maintained at room temperature for at least 1 hour in 
oxygenated artificial cerebrospinal fluid (aCSF) containing the following: 126mM NaCl, 
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2.5mM KCl, 2.0mM MgCl2, 1.25mM NaH2PO4, 26mM NaHCO3, 10mM glucose, 2.0mM 
CaCl2 (Brust et al., 2007). Oxygenation was accomplished by continually bubbling the solution 
with 95% O2/5% CO2. 
2.4  Drug treatments 
2.4.1  Ex vivo hypoxic drug incubations  
Hippocampal slices were incubated with the following treatments: dimethyl sulfoxide (DMSO, 
vehicle control, Sigma, St. Louis, MO) and metformin hydrochloride (Metformin, Abcam) at 
5µM. Incubation times for electrophysiology experiments and histology experiments varied 
and are specified. Metformin hydrochloride was first dissolved in double-distilled water 
(ddH2O), before the same volume of DMSO used to dissolve the other drugs was added, and 
this solution was now added to aCSF. The final concentration of DMSO was <0.1% in each 
treatment.  
2.4.2  Ex vivo acute drug incubations  
Hippocampal slices were incubated with the following treatments: dimethyl sulfoxide (DMSO, 
vehicle control, Sigma, St. Louis, MO), N6-cyclopentyladenosine (CPA) used as a selective 
adenosine A1 receptor agonist at 100nM and metformin hydrochloride (Abcam) at 5μM. 
Incubation times between electrophysiology experiments and histology experiments varied and 
are specified. All drugs with the exception of metformin hydrochloride were dissolved first in 
DMSO before being added to aCSF. Metformin hydrochloride was first dissolved in ddH2O, 
before the same volume of DMSO used to dissolve the other drugs was added, and this solution 
was now added to aCSF. The final concentration of DMSO was <0.1% in each treatment.  
2.4.3  In vivo chronic injections  
Animals were injected with the following treatments: dimethyl sulfoxide (DMSO)/Saline 
(phosphate buffer saline 1X), N6-cyclopentyladenosine (CPA) (3mg/kg), CPA (3mg/kg) + 
metformin (2mg/kg), CPA (3mg/kg) + metformin (5mg/kg) and CPA (3mg/kg) + metformin 
(10mg/kg). CPA was first dissolved in DMSO before PBS was added, however metformin was 
17 
 
dissolved in PBS first and the same volume of DMSO used to dissolve CPA was added to these 
treatments and our vehicle control DMSO/Saline group. Injected i.p. volumes typically ranged 
from 0.2-0.35ml per injection and was dependent on animal weight.    
2.5  Electrophysiology 
Hippocampal slices were prepared as detailed in Section 3 and submerged in an 
electrophysiology recording chamber with constant perfusion of oxygenated aCSF (3mL/min). 
Depending on the protocol used for experiments, the same concentration of drug treatment that 
was used for drug incubations was either added to aCSF and perfused continuously for the 
duration of the experiment or added directly to aCSF containing the slice for preincubation. 
Field excitatory postsynaptic potentials (fEPSPs) were evoked by orthodromic stimulation of 
the Schaffer collateral pathway using a bipolar tungsten stimulating electrode and recorded 
using Clampex 9.0 software (Axon Instruments, Foster City, CA). A pulled glass recording 
microelectrode filled with aCSF (resistance 1-3MΩ) was placed in CA1 stratum radiatum, 
which recorded fEPSPs induced by Schaffer collateral stimulation. fEPSPs were evoked for 
0.1ms every 30s throughout recordings.  
fEPSP signals were amplified 1000 times with an AC amplifier, band-pass filtered at 0.1-
1000Hz, digitized at 10kHz using a Digidata 1440A digitizer (Axon Instruments) and saved to 
a computer as a Clampex 9.0 (Axon Instruments) file. The fEPSP response for each slice was 
tested using low voltage stimulation (5-6 volts) initially to test the responsiveness of the slice, 
high voltage stimulation was not used (9 volts+). This was to decrease the chance of random 
increases in population spikes during recording and to prevent extraneous damage to the axonal 
tracts of the slice; both of which would directly affect the level of fEPSP response recorded. 
Scale bar vertical calibration: 0.5 mV, horizontal calibration: 30 ms. Baseline fEPSP was set 
to 40-50% of the maximal fEPSP response per slice. The collected fEPSP data was analyzed 
using Clampfit 9.0 (Axon Instruments). fEPSP slopes were normalized to the mean of the 10 
sweeps (5 min) immediately preceding drug infusion. The mean normalized fEPSP slope was 
plotted as a function of time with error bars representing the standard error of the mean (SEM). 
Sample traces are the average of 5 sweeps from a representative recording from each treatment 
group. All histograms show the mean normalized percent inhibition from baseline (+/- SEM). 
Statistical significance was assessed using one-way analysis of variance (ANOVA) with 
Tukey-Kramer post-hoc analysis test where p<0.05=*, p<0.01=**, p<0.001=***.   
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2.5.1  Effect of concentration of metformin on signalling                                                    
The effect of metformin on fEPSP signalling using hippocampal slices was tested at five 
different concentrations (0.1nM, 1nM, 10nM, 100nM and 1μM) using electrophysiology 
techniques. After a stable baseline signal was achieved, each metformin concentration was 
added to aCSF and allowed to perfuse through the recording chamber for 20 minutes. The last 
10 sweeps (5 minutes) of each treatment were averaged and compared to the baseline response. 
One-way ANOVA statistical testing was performed with the Tukey-Kramer post-hoc analysis 
test for comparison of fEPSP signalling between concentrations. 
In a second set of experiments the effect of consecutive increases in metformin concentration 
was tested using electrophysiology techniques on hippocampal slices. After a stable baseline 
signal was recorded, metformin was perfused through aCSF in 15-minute intervals using 1μM, 
10μM and 30μM concentrations. The average of the last 10 sweeps (5 minutes) of each 
treatment was averaged and compared to the baseline response. One-way ANOVA statistical 
testing was performed with the Tukey-Kramer post-hoc analysis test to compare fEPSP 
signalling between concentrations. 
2.5.2  Ex vivo hypoxia and metformin effects                                                                            
Using hippocampal slices to test the effect of hypoxia, we recorded a steady stable baseline 
initially with normal oxygenated aCSF before perfusing the slice for 20 minutes with a 
deoxygenated/hypoxic aCSF solution which was bubbled with 95% N2, 5% CO2. Following 
this the slice was again perfused with oxygenated aCSF which was continuously bubbled with 
95% O2, 5% CO2 for approximately 1 hour and the changes to the electrophysiological fEPSP 
response was recorded. The average of the last 10 sweeps (5 minutes) of each segment of the 
experiment before the environmental conditions of the slice was changed were averaged and 
compared to the baseline response. One-way ANOVA statistical testing was performed with 
the Tukey-Kramer post-hoc analysis test to compare fEPSP signalling between baseline, 
hypoxia and post-hypoxia interventions.  
To study the effect of metformin during hypoxic stimulation, metformin at 5μM concentration 
was added 5 minutes into the 20-minute hypoxia period in one experiment and in another, the 
slice was pre-incubated with metformin (5μM) for a minimum of 30 minutes prior to hypoxia 
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treatment. We chose to introduce metformin at 5 min, as this was found to be the peak period 
when intracellular MAPK cascades and protein phosphatases were activated (Brust et al., 2006, 
Brust et al., 2007). Once again, the average of the last 10 sweeps (5 minutes) of each treatment 
was averaged and statistical testing used to compare fEPSP changes with and without 
metformin during and after hypoxia. 
2.5.3  Ex vivo transient adenosine increases and metformin effects                                  
Also using hippocampal slices and electrophysiology, first, a stable baseline was attained by 
recording fEPSP for a minimum of 20 minutes. CPA (100nM) was then perfused through aCSF 
for 10 minutes and following this normal aCSF containing no drugs was perfused onto the slice 
during the 45-minute washout period.   
In the second round of experimentation, after 1-hour preincubation with metformin (5μM), a 
stable baseline was recorded, following which CPA (100nM) was again perfused for 10 
minutes, and a 45-minute washout period with normal aCSF followed. However, in this 
experiment metformin (5μM) was perfused continuously throughout the experiment to ensure 
the slice was continuously bathed in metformin throughout the experiment.  The changes in 
fEPSP were compared within each experiment between baseline, CPA (100nM) treatment and 
the washout period as well as between experiments to compare the effect on fEPSP with and 
without metformin.  
2.6  Histology 
2.6.1  Propidium Iodide staining  
Propidium Iodide (PI) is an effective fluorescent marker for indiscriminate cell death due to 
the fact that it only enters cells with disrupted plasma membranes. Hippocampal slices were 
prepared as described in Section 3 and utilized for this staining procedure. It produces strong 
fluorescence when excited by green light. An increase in fluorescence is indicative of increased 




2.6.1.1  Ex vivo hypoxia and metformin 
We wanted to examine the effect of hypoxia intervention and metformin (5μM) treatment on 
cell survival when metformin was given 5 minutes into hypoxia treatment as compared with 
metformin preincubation prior to the induction of hypoxia treatment. The methods used were 
adapted from Pugliese et al. (2009). All procedures otherwise were followed as detailed above 
in 6.2 with the addition of a fourth treatment group of dimethyl sulfoxide (DMSO) acting as 
our time control which was kept in oxygenated aCSF for the duration of the experiment. 
Following hypoxia treatment, slices were treated with fresh oxygenated aCSF for 2 hours 
before 5μg/mL propidium iodide (Sigma) was added and incubated with the slices for 1 hour. 
The slices were then rinsed in aCSF and fixed in 4% paraformaldehyde in 1X PBS at 4 degrees 
Celsius overnight. 
2.6.1.2  Ex vivo transient adenosine increases and metformin 
We wanted to examine the effect of CPA (100nM) and metformin (5μM) treatment individually 
and in combination with each other on cell survival. The methods used were adapted from 
Pugliese et al. (2009) and Stockwell et al. (2016).  All procedures otherwise were followed as 
detailed above in 6.3 with the exception of incubation times.  The following drug treatments 
were added: dimethyl sulfoxide (DMSO), metformin (5μM), CPA (100nM), metformin (5μM) 
+CPA (100nM). Slices were incubated in DMSO, metformin (5μM) and CPA (100nM) for 1 
hour, however for one treatment group metformin (5μM) was added first for 30 minutes before 
CPA (100nM) was added to pre-existing metformin (5μM) incubated aCSF for 1 hour. CPA  
treatment was administered for 1 hour at 100nM because previous experiments had revealed 
that CPA administration at 500nM for 30-45 minutes was sufficient to reduce the surface 
expression of GluA1 and GluA2 (Z. Chen et al., 2014); while also activating p38 mitogen-
activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) (activated at 50nM CPA 
administration for 10 minutes (Brust, Cayabyab, & MacVicar, 2007; Brust, Cayabyab, Zhou, 
& MacVicar, 2006)) all of which are implicated in adenosine receptor mediated cytotoxic 
signalling pathways. aCSF was continuously kept oxygenated with 95% O2, 5% CO2. 
Following 1-hour drug incubation treatment, aCSF was replaced with fresh oxygenated aCSF 
and the slices were incubated for 3 hours. In the final hour of incubation 5μg/mL propidium 
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iodide (Sigma) was added to the aCSF. After this, slices were rinsed in aCSF and fixed in 4% 
paraformaldehyde in 1X PBS at 4 degrees Celsius overnight. 
2.6.1.3  Propidium Iodide imaging and analysis  
Slices were washed 3 x 10 minutes in 1X PBS, and mounted-on glass microscope slides (VWR) 
and sealed using Prolong Gold Antifade reagent (Invitrogen). After the addition of PI, all 
subsequent procedures were completed in the dark to prevent photobleaching.  
Hippocampal slices were imaged using a Zeiss LSM700 laser scanning confocal microscope 
(Carl Zeiss, Germany) using a green light (543nm) to induce PI fluorescence during imaging. 
The whole hippocampus was imaged in pieces using a 10x objective lens, and images of CA1 
pyramidal neurons were obtained using the Zeiss-Apochromat 63x/1.4 oil objective lens (Carl 
Zeiss). CA1 images were acquired as Z stack images of 30μm at 100μm depth into the 
hippocampal slice with each z stack image taken in 2μm increments. Two z stack images were 
taken along CA1 for each slice, with multiple slices imaged per treatment group per animal.  
Data was collected with Zeiss Zen 2009 version 5.5 software (Carl Zeiss) and was analyzed 
using ImageJ. Z-stack images closest to the outer top and bottom of the hippocampal slice were 
not utilized for analysis as the neuronal damage in those areas was enhanced by the slicing 
procedure. Images from the inner-most 20µm (~150μm approx. deep into the slice) were 
combined as maximum intensity projections and were compared between treatment groups 
using densitometry analysis. Collected densitometry data was normalized to DMSO time 
control slices that were treated along with each experiment. Data was graphed as a percentage 
of the time control value and analyzed for significance against this control value (up to 100%) 
where p<0.05=*, p<0.01=**, p<0.001=***, p<0.0001=****. Full hippocampal slice images 
were assembled as montages of the entire hippocampus using Adobe Photoshop CS6 (Adobe 
Systems, Mountain View, CA). All images were taken with equal dimensions from the CA1 
pyramidal cell layer, sampled at 12 bits, and were the average of two images taken side by side 





2.7   Biochemistry 
2.7.1  In vivo chronic co-administration of adenosine with metformin                              
Animals from the same chronic injection testing group were taken, anaesthetized with 
halothane and decapitated. This consisted of one animal from each group: DMSO/Saline, CPA 
(3mg/kg), CPA (3mg/kg) + metformin (2mg/kg), CPA (3mg/kg) + metformin (5mg/kg) and 
CPA (3mg/kg) + metformin (10mg/kg). Following preparation, each brain was then sliced in 
ice-cold sucrose solution and hippocampal slices were isolated according to Section 2.3.  
Surface biotinylation, biochemistry preparation and analysis 
Hippocampal brain slices after preparation were kept in aCSF that was continuously 
oxygenated with 95% O2, 5% CO2 to equilibrate for 1 hour after slicing. Following this, slices 
were rapidly cooled to 4 degrees Celsius with 4-degree Celsius aCSF and treated with NHS-
SS-Biotin (0.5mg/mL, Thermoscientific) for 1 hour at 4 degree Celsius. The biotin reaction 
was quenched with quenching buffer at pH 8.3 containing 192mM glycine and 25mM Tris. 
Slices were then transferred to homogenization tubes containing 1% NP-40 detergent 
homogenization buffer at pH 8.0 which contained 50mM Tris, 150mM NaCl, 1mM EDTA, 
1mM NaF, and the following protease inhibitors: 1mM PMSF, 10g/L aprotinin, 10g/mL 
pepstatin A, 10g/mL leupeptin, 2mM Na3VO4, 20mM sodium pyrophosphate, 3mM 
benzamidine hydrochloride and 4mM glycerol 2-phosphate. 
Western blotting, imaging and analysis 
Braford Assay was performed with DC Protein assay dye (Bio-Rad) to determine the protein 
concentration in each of the four/five treatment group lysates. Following this assay, 500μg 
protein lysate diluted in lysis buffer was added to Streptavidin agarose beads (Thermo 
scientific) and rotated overnight continuously at 4 degrees Celsius. The beads were then 
washed 3 times the following morning with lysis buffer containing 0.1% NP-40.  A 50μl 
volume of 2X Laemmli sample buffer (Bio-Rad) was added and the samples were boiled for 5 
minutes at 95 degrees Celsius.  Samples were loaded into 10% SDS-PAGE gels and run for 15 
minutes at 80V and 45 minutes at 160V or until the sample buffer has migrated to the bottom 
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of the glass plate.  Proteins were transferred from the gel to PVDF membranes at 4 degrees 
Celsius on ice at 0.23A for 2.5 hours.  Each membrane was then blocked in 5% blocking buffer 
consisting of 2.5g skimmed milk powder in Tris buffer saline with Tween-20 (TBST) for 1 
hour.  Then the membrane was incubated overnight in the appropriate primary antibody at 
1:1000 dilution (e.g., A1R, Sigma, GAPDH, Sigma) at 4 degrees Celsius, followed by 
incubation of the appropriate secondary antibody for 1 hour at room temperature the next day. 
It was then rinsed in TBST 3 times x 10 minutes each and imaged using a Bio-Rad ChemiDoc 
imaging system. Following imaging, the whole cell lysate sample membrane was rinsed again 
3 times x 5 minutes each and incubated for 1 hour with GAPDH (Sigma) at 1:1000 dilution, 
and again following this the membrane was rinsed 3 times for 10 minutes each before the 
secondary antibody was added also at a 1:1000 dilution for 1 hour (Sigma). The membrane was 
then again rinsed 3 times x 5 minutes per rinse, and the membrane was imaged with the Bio-
Rad ChemiDoc imaging system. Analysis was performed using Bio-Rad Image Lab software 
and ImageJ (NIH). Graphs were constructed using GraphPad Prism 7 (GraphPad) with data 
presented as mean +/- SEM. Statistical significance was performed with a one-way ANOVA 
test and Tukey-Kramer post-hoc analysis test.  
2.8.  Behavior Experiments 
Male Sprague Dawley rats post-natal day 28-35 were utilized weighing between 200-300g. 
Animals were handled once daily between day 28-35 for 5-7 days to familiarize the animal 
with the handler and all maneuvers the animal would undergo during treatment and/or 
behavioral testing. Animals were then injected once daily for 7 days with the following drugs: 
DMSO/Saline vehicle control, CPA (3mg/kg), CPA (3mg/kg) and metformin (2mg/kg), CPA 
(3mg/kg) and metformin (5mg/kg) or CPA (3mg/kg) and metformin (10mg/kg). On day 8 and 
9 animals underwent behavioral tests of Y-Maze, Forced Swim and Open Field testing.  
To begin, on the morning of testing animal cages were placed in the testing room with HEPA 
filters removed for 1 hour undisturbed to allow for acclimatization to room light intensities, 





2.8.1  Y-Maze 
The Y-maze was constructed using corrugated cardboard with three 45 cm x 12 cm long 
equidistant 120-degree arms located around a central point. Spatial cues of a colored rectangle 
and grey asterisk were placed in close vicinity of the maze on opposing room walls to aid with 
spatial awareness/perception of the animal when maneuvering throughout the maze. All other 
spaces concurrent to the Y-maze that would provide any confounding visual cues were covered 
from eyesight of the animal by a white sheet cover.  
Following initial set up of the Y-Maze, one arm was blocked and sealed off to only allow for 
exploration of 2 arms of the maze. Each animal was placed in the start arm of the Y-Maze and 
allowed to explore the start and old arms without influence for 15 minutes during trial 1. 
Animals were then removed from the maze following the conclusion of the trial and placed 
back into their home cages for a minimum of 90 minutes to rest and accommodate any gained 
information into spatial memory. Each animal was then returned to the Y-maze with all arms 
open and no restrictions to access and could explore the maze freely for 5 minutes during trial 
2. Both trials were recorded using a digital camera, videos were saved, and videos were scored 
manually and using Ethovision XT 12 software.  
2.8.2  Open Field  
The open field was constructed using corrugated cardboard with a defined field consisting of 
16 equal squares measuring 56cm x 56cm. The centermost 4 squares were then segmented 
again to create an innermost square measuring 28cm x 28 cm. All other spaces concurrent to 
the open field that would provide any confounding visual cues were covered from eyesight of 
the animal by a white sheet cover. Each animal was placed in the innermost center square of 
the field and allowed to explore the full field without restriction for 10 minutes during the trial. 
Following this the animal was then removed from the field and returned to its home cage. The 
trial was recorded using a digital camera, videos were saved and scored manually and using 





2.8.3  Forced Swim  
The forced swim tank was constructed using plexiglass which had a dimension of 30 cm x 30 
cm with walls measuring 60 cm high. The tank was filled with water at a temperature of 23-25 
degrees Celsius to a height appropriate for the animal to be tested. At minimum the height of 
the water is equal to the length of the animal from the tip of its nose to the tip of its tail. Animals 
were placed in the tank for 10 minutes continuously throughout the trial. Following the trial, 
the animal was removed from the tank, dried using towels and returned to their home cage to 
rest. The trial was recorded using a digital camera, these videos were saved and scored 
manually. 
2.9  Radioligand Binding Assay 
After hippocampal slice preparation as detailed in Section 3, slices were rapidly frozen in liquid 
nitrogen and later immersed in homogenization buffer (50mM Tris-HCl, NaCl 100mM, 1mM 
Ethylenediaminetetraacetic acid (EDTA), double distilled water (ddH2O)) and homogenized 
using a homogenizer and dunce motions. This solution was then transferred to an 
ultracentrifuge tube and spun down at 26500rpm for 30 minutes at 4 degrees Celsius. The 
supernatant was removed and again the pellet was resuspended in binding buffer (75mM Tris-
HCl, 12.5mM MgCl2, 1mM EDTA, 1mg/mL bovine serum albumin (BSA), and ddH2O) and 
homogenized, before it was spun a second time in an ultracentrifuge tube at 26500rpm for 30 
minutes at 4 degrees Celsius. The supernatant was removed, and the pellet was resuspended in 
binding buffer. A Bradford assay was run to ascertain protein concentration per rat 
hippocampal sample and the volume needed to use 125μg/mL of protein for the assay was 
calculated.  
DPCPX is a selective adenosine A1 receptor antagonist.  We used a tritiated form of this 
compound, sourced from Perkin-Elmer for our radiolabeling binding assay. We compared the 
binding profile of H3-DPCPX to A1R using hippocampal lysates when we increased 
concentrations of cold-DPCPX or cold-metformin. H3-DPCPX was diluted to a 1:100 
concentration in binding buffer. Six concentrations of cold/non-radioactive DPCPX and 
metformin were used to compare the binding profiles of DPCPX and metformin individually 
to the adenosine A1 receptor.  These were: 0.1nM, 1nM, 10nM, 100nM, 1μM and 10μM. Each 
sample was mixed with the appropriate volume of H3-DPCPX and cold-DPCPX or H3-DPCPX 
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and cold-metformin and incubated for 2 hours at room temperature. There were 2 negative 
controls in this experiment, our first control was a vial containing only binding buffer and no 
drugs, and our second control was a vial containing binding buffer and H3-DPCPX.  The 
samples were then filtered in a drum using vacuum filtration, rinsed with 1X PBS and incubated 
in scintillation vials overnight. The following day these scintillation vials were placed in a 
scintillation counter and radioactive counts in counts per minute (cpm) were read and recorded 
from each sample. All values were normalized according to the control value which was a 
measure of background radiation.  
Data Analysis 
Each sample was run multiple times with both cold-DPCPX and cold-metformin in comparison 
to H3-DPCPX, using a total of 8 individual samples of the same age from the same batch of 
animals. All values after normalization were averaged and plotted as a linear regression in 














3.1  The effect of various concentrations of metformin on fEPSP signalling 
To investigate the effect of metformin on adenosine signalling, we looked at the fEPSP 
response when different concentrations of metformin were administered. Hippocampal CA1 
neurons when stimulated in the presence of 0.1nM-30μM of metformin showed an increase in 
field excitatory postsynaptic potential (fEPSP) (Figure 3.1 C). When the last 10 traces (5 
minutes) of each experiment was averaged and analysed using one-way ANOVA statistical 
testing, significant fEPSP increases were noted with metformin treatment at 1μM and 10μM. 
However, rapid decreases in fEPSP signalling were observed at the 30μM concentration, 




Figure 3.1: Metformin treatment significantly increased fEPSP signalling when perfused 
at the 1μM and 10μM concentrations. N=6 recordings from individual slices from different 
animals for metformin 0.1nM, 1nM and 10nM. N=4 from individual slices from different 
animals for metformin 100nM. N=8 recordings from individual slices from different animals 
for metformin 1μM, 10μM and 30μM consecutive responses. Data are mean ± SEM. Vertical 
calibration: 0.5 mV. Horizontal calibration: 30 ms. 
Five different concentrations of metformin (0.1nM, 1nM, 10nM, 100nM, 1μM) were added to 
aCSF and perfused on to fresh hippocampal slices for 20 minutes, and the changes in fEPSP 
signalling were observed and analysed. In a second experiment, three different concentrations 
of metformin (1μM, 10μM and 30μM) were added to aCSF and perfused on to fresh 
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hippocampal slices for 15 minutes consecutively, and the changes in fEPSP signalling were 
observed and analysed using one-way ANOVA statistical testing. Sample traces of fEPSP 
responses are shown in Figure 3.1 A, however this data is summarised in Figure 3.1 C.  A 
significant increase from baseline fEPSP signalling was observed at 1μM and 10μM 
concentrations. 
From this study we were able to deduce that metformin treatment produces a significant effect 
between 1-10μM when perfused on to the slice through aCSF for 15-20 minutes. A dose 
response curve (not shown) gave an EC50 value of 4.89μM, therefore we decided for the 
remainder of our drug studies to use a 5μM concentration of metformin. Figure 3.1 B shows 
the effect of metformin (5μM) on fEPSP after 20 minutes of administration, which caused an 
increase in fEPSP. Additionally, we had observed in this experiment that metformin (5μM) 
was able to cause a persistent and sustained increase in fEPSP for an additional 20 minutes 
with constant metformin 5μM perfusion (not shown).   
3.2  The effect of metformin during hypoxia treatment 
Pre-clinical studies revealed that metformin administration in stroke animal models resulted in 
neuroprotective benefits but did not specify a mechanism of action beyond activation of AMPK 
(Li et al., 2010), neurogenesis and angiogenesis induction (Liu, Tang, Zhang, et al., 2014) 
(Abdelsaid et al., 2015) and increased microglial response (Jin et al., 2014). We utilised 
electrophysiology and histology techniques with hypoxia treatments and different metformin 








3.2.1 Effect of hypoxia on fEPSP with different metformin intervention 
time points 
 
Figure 3.2.1: Metformin (5μM) had no effect on hypoxia-induced synaptic depression but 
preincubation with metformin at 5μM prevented hypoxia-induced adenosine-mediated 
postsynaptic potentiation. Recordings were from individual slices from different animals 
with n=14 for hypoxia treatment control, n=10 for metformin (5μM) treatment administered 5 
minutes into hypoxia and n=13 for metformin (5μM) preincubation and hypoxia treatment. 
Sample traces for each experiment are shown in Figure 3.2.1 A. Data are mean ± SEM. Vertical 
calibration: 0.5 mV. Horizontal calibration: 30 ms. 
A full comparison of each experiment showing fEPSP response prior to, during and after 20-
minute hypoxia treatment (95% N2, 5% CO2) without metformin (5μM), with metformin (5μM) 
added 5 minutes into hypoxia treatment and with the preincubation of metformin (5μM) for a 
minimum of 30 minutes prior to the start of the experiment is shown in Figure 3.2.1 B. 
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While metformin was found in the literature to be neuroprotective against stroke in the MCAO 
model (Jin et al., 2014; Li et al., 2010; Liu, Tang, Zhang, et al., 2014), we found that our 
metformin-hypoxia experiments gave rise to some interesting results. In comparing the last 10 
fEPSP traces (5 minutes) of hypoxia treatment, without metformin, when metformin (5µM) 
was added 5 minutes into hypoxia or with slices that were preincubated with metformin (5μM), 
we found that metformin treatment resulted in the same level of fEPSP in comparison to the 
control hypoxia treatment (Figure 3.2.1 C).  There was no statistically significant difference 
in fEPSP signal at the end of hypoxia between all three treatments (p=0.9). It is therefore 
notable that metformin (5μM) treatment did not affect synaptic depression during hypoxia 
(Figure 3.2.1 C), as this is normally attributable to A1R stimulation and A1R-mediated 
neurotoxicity (Z. Chen et al., 2014) 
Now when analysing the effect of metformin (5μM) during normoxia, we compared the last 10 
fEPSP traces (5 minutes) of normoxia treatment between all three experiments (Figure 3.2.1 
D). We noted that there was an increase in fEPSP that was observed in the control experiment 
which was also present when metformin (5μM) was added 5 minutes into hypoxia, and this 
increase was found to be statistically significant (Figure 3.2.1 D, where p<0.05=*). This 
increase in fEPSP after hypoxia treatment was first observed by Hsu and colleagues (Hsu & 
Huang, 1997), and has been since termed adenosine-induced postsynaptic potentiation (APSP) 
by Qin and colleagues (Qin et al., 2019, submitted). Moreover, our results showed that there 
was no significant difference in fEPSP signalling at the end of normoxia washout treatment 
between the control and metformin (5μM) response when it was added 5 minutes into hypoxia 
treatment. On the other hand, when metformin (5μM) was added to slices for a minimum of 30 
minutes prior to the start of the hypoxia experiment and also perfused continuously throughout, 
our results differed. 
Interestingly the development of post-hypoxic APSP was affected when slices were 
preincubated with metformin (5μM) prior to the induction of hypoxia. Signalling transmission 
returned to baseline and remained constant for 30 minutes until the end of the experiment, and 
there was no statistically significant difference between the fEPSP signal at the baseline as 
compared to the fEPSP signal at the end of normoxia (Figure 3.2.1 D, where p=0.82).  
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Our results overall showed that the preincubation of hippocampal slices with metformin (5μM) 
prevented the development of adenosine-induced post-synaptic potentiation (APSP) during 
normoxic washout but the addition of metformin (5μM) during hypoxia did not. 
3.2.2 Effect of hypoxia on indiscriminate cell death with different metformin 
intervention time points  
Given the interesting finding from our electrophysiology results (Figure 3.2.1), we decided to 
mirror this experiment and use propidium iodide staining and confocal imaging to determine 
the levels of indiscriminate cell death. We thought this would allow us to understand the effect 
of metformin on hypoxia treatment, and if time of administration played a crucial role in the 
recovery of cells as our electrophysiology experiments (Figure 3.2.1), and previous citations 
in the literature had led us to believe (Li et al., 2010). 
In this additional experiment we pre-incubated slices with metformin at 5μM for one hour 
before adding the hypoxic aCSF solution. To other slices we incubated with DMSO for the 
same length of time as a control. And in the last two treatment groups we induced hypoxia in 
one and added metformin (5μM) after 5 minutes of hypoxia in the other. We then added 
propidium iodide and observed the levels of fluorescence using a confocal microscope, where 
increases in fluorescence are directly proportional to increases in cell death (Figure 3.2.2 A 
and B).  We quantified this fluorescence using densitometry, and analysed our results using 
statistical one-way ANOVA testing in Figure 3.2.2 C where p<0.05=*, p<0.01=**, 




Figure 3.2.2: Metformin (5µM) preincubation prevented hypoxia-mediated cell death. 
N=4 individual slices per treatment group. 
Hippocampal slices were pre-incubated with metformin (5µM) or DMSO for 1 hour. DMSO-
treated slices remained immersed in oxygenated aCSF while all other treatment group slices 
were immersed in hypoxic aCSF for 20 minutes. One treatment group received metformin at 
5μM 5 minutes into the 20-minute hypoxic treatment. Following this all solutions were 
replaced with normoxic aCSF for 45 minutes with or without metformin (5µM) to mirror our 
earlier electrophysiology experiments. Propidium iodide staining was used to quantify the 
overall cell death levels by measuring fluorescence intensities using confocal microscopy.  
With confocal microscopy, a significant decrease in propidium iodide red fluorescence was 
observed with metformin (5μM) preincubation (p=0.0003) as compared to when metformin 
(5μM) was added 5 minutes to hypoxia treatment (p=0.0135) or not at all (Figure 3.2.2 C). It 
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is important to note that while metformin (5μM) treatment given 5 minutes into hypoxia 
treatment did significantly decrease the level of fluorescence as compared to our hypoxia 
positive time control result, metformin preincubation still yielded greater neuroprotection and 
resulted in lower levels of cell death in comparison. 
3.3. The effect of metformin during transient endogenous adenosine 
increases  
Our hypoxia study with different metformin intervention time points yielded interesting results 
where we found slices preincubated with metformin at 5μM showed significant improvements 
in neuronal cell health. Therefore given that it has previously been shown that both hypoxia 
and CPA treatment cause neuronal death due to activation of A1Rs (Stockwell et al., 2016), we 
decided to test the effect of metformin preincubation on CPA-induced A1R activation.   
3.3.1 Effect of metformin on fEPSP during adenosine release 
First, we looked at the effect of metformin (5μM) with CPA at 100nM on the field excitatory 
postsynaptic potential (fEPSP). We wanted to determine if metformin would prevent CPA-
induced synaptic depression similar to effects observed with the A1R antagonist DPCPX in the 
presence of adenosine (Brust et al., 2006). DPCPX was also shown to cause statistically 





Figure 3.3.1: Preincubation with Metformin (5μM) treatment did not prevent CPA-
induced decreases in fEPSP signalling.  Recordings were from individual slices from 
different animals with N=8 for CPA (100nM) treatment and N=6 for metformin (5μM)+CPA 
(100nM) treatment. Data are mean ± SEM. Vertical calibration: 0.5 mV. Horizontal calibration: 
30 ms. 
Hippocampal slice fEPSP signals were recorded when CPA at 100nM was added to aCSF 
solution and perfused for 10 minutes at a rate of 3mL/min. This was then compared to 
hippocampal slices pre-incubated with metformin (5μM) for 30 minutes – 1 hour prior to the 
start of electrophysiology experiments. Baseline fEPSP signals were recorded and the slice was 
then perfused with aCSF containing 100 nM of CPA also in the presence of metformin (5μM). 
If the slice had undergone metformin preincubation, then metformin (5μM) was perfused 
throughout the experiment.  
In comparing the fEPSP response to CPA (100nM) with or without metformin (5μM) by 
averaging the last 10 traces and using one-way ANOVA statistical testing, we found that 
hippocampal CA1 neurons when stimulated in the presence of CPA at 100nM showed a 38.1% 
reduction in fEPSP. This is a repetition of previous experiments conducted in our lab using 
CPA at 500nM (Stockwell et al., 2016). Interestingly, metformin at 5μM in the presence of 
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CPA (100nM) caused a statistically significant greater decrease in fEPSP (-53.4%) as 
compared to the CPA (100nM) response alone (Figure 3.3.1 C, where p=0.01).  
On the other hand, when comparing between the fEPSP responses following CPA (100nM) 
treatment, we found that at the end of the 45-minute washout period there was no statistically 
significant difference in fEPSP response when metformin (5μM)+CPA (100nM) was used as 
compared to CPA (100nM) alone (Figure 3.3.1 D, where p=0.7). 
3.3.2. Effect of metformin on indiscriminate cell death during adenosine 
release  
Our earlier electrophysiological finding (Figure 3.3.1 C) was an interesting finding which 
allowed us to investigate the possibility of metformin (5μM) exacerbating cell death in the 
presence of CPA (100nM). 
Therefore, mimicking our CPA (100nM) electrophysiology study, we treated hippocampal 
slices with DMSO, CPA (100nM), metformin (5μM) and metformin (5μM)+CPA (100nM) 
and added propidium iodide staining to observe the levels of cell death. This would allow us to 
ascertain whether metformin treatment during transient adenosine A1 receptor stimulation 
(100nM of CPA for 30 min) is neuroprotective or not. Our results are shown as follows in 




Figure 3.3.2: Metformin (5μM) preincubation prevented CPA-induced cell death. N=4 
individual slices per treatment group.    
Hippocampal slices were preincubated with metformin (5μM) or DMSO for 1 hour. CPA at 
100nM was added to the required treatment groups accordingly for 30 minutes. All drugs were 
subsequently washed out with untreated aCSF for 2 hours, before propidium iodide staining 
was used in the final hour to quantify the overall levels of cell death via intensity of 
fluorescence. We quantified this fluorescence using densitometry, and analysed our results 
using statistical one-way ANOVA testing in Figure 3.3.2 C where p<0.05=*, p<0.01=**, 
p<0.001=***, p=0.0001=****.  
A statistically significant decrease in propidium iodide red fluorescence was observed with 
metformin preincubated slices that were treated with CPA at 100nM (Figure 3.3.2 C).  
Interestingly, treatment with metformin alone did not induce any significant neuronal damage, 
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and fluorescence levels were very similar to DMSO control (p=0.81) or combined CPA and 
metformin treatments (p=0.68). 
3.4. The effect of metformin on post-stroke cognition, mood and locomotion 
after chronic CPA administration  
In the literature, one study noted that chronic metformin exposure 24 hours after MCAO led to 
increased neurogenesis, angiogenesis and cell survival following stroke (Jin et al., 2014). They 
attributed this neuroprotection to be mediated by adenosine monophosphate activated protein 
kinase (AMPK).  
Based on our ex vivo findings and reports in the literature we wanted to investigate the effect 
of metformin in vivo with chronic supraphysiological increase of adenosine levels similar to 
what would be expected following stroke; so, we intraperitoneally injected animals with CPA 
(A1R agonist) at 3mg/kg for 7 days.  
With such variations in metformin dosing within the literature ranging from 25mg/kg to 
500mg/kg we decided to use 3 concentrations (2mg/kg, 5mg/kg, 10mg/kg) in our study. We 
chose these concentrations of metformin because our animals were not T2D sufferers and we 
did not want to prematurely induce lactic acidosis (metformin’s primary adverse effect) in our 
animals. The maximum recommended therapeutic dose for T2D patients was 2,550mg/day and 
for a 70kg adult male this was calculated to be between 35-40mg/kg/day.  
Our control was DMSO/Saline because all drugs were dissolved in DMSO first and then diluted 
with phosphate buffer saline to the appropriate volume.  
3.4.1. Metformin at 10mg/kg significantly improves CPA-induced cognitive 
deficits (Y-Maze) 
First, we used the Y-Maze behavior test to assess the effect of adenosine and metformin on 
hippocampal dependent spatial memory. We know there are large subpopulations of 
adenosine receptors within the hippocampus and most of the cognitive deficits observed 
following stroke often originate from neuronal damage in this region of the brain. Using the 
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knowledge gained from our earlier ex vivo results, we knew that metformin binds adenosine 
receptors and interferes with their signalling mechanisms to confer neuroprotection.  
Specifically, we found that metformin (5μM) preincubation prevented APSP generation 
(Figure 3.2.1 D), and neuronal cell death following A1R stimulation (Figure 3.2.1 C and 
3.3.2 C). Therefore, we expected to see significant improvements in cognition and 
functioning with metformin treatment after  CPA-induced chronic insult which we knew to 
significantly affect the hippocampus (Stockwell et al., 2017). Our results are shown in Figure 
3.4.1. 
 
Figure 3.4.1: Rats treated with CPA at 3mg/kg and Metformin at 10mg/kg concurrently 
showed the greatest cognitive improvement as compared to rats treated with metformin 
at 2mg/kg and CPA at 3mg/kg or CPA at 3mg/kg alone. N=11 individual rats per treatment 
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groups – DMSO/Saline, CPA (3mg/kg)+Metformin (5mg/kg). N=7 individual rats per 
treatment groups – CPA (3mg/kg). N=9 individual rats per treatment group – CPA 
(3mg/kg)+Metformin (2mg/kg). N=10 individual rats per treatment groups - CPA 
(3mg/kg)+Metformin (10mg/kg). 
Rats were treated with CPA alone (3mg/kg), CPA and Metformin at 2mg/kg, 5mg/kg and 
10mg/kg or DMSO/Saline once daily for 7 days. Behavior testing was conducted on day 8. 
Animals were allowed to explore two arms of the Y-maze for 15 minutes, removed from the 
maze and given 1.5 hours to consolidate any information learned to spatial memory. Following 
this, animals were placed back in the Y-maze, with all three arms of the maze open for 5 
minutes. The percentage of time each animal spent in each of the three arms during this period 
was analysed using a one way-ANOVA test.  
Y-Maze Testing for hippocampal-dependent spatial memory and learning showed CPA 
(3mg/kg) and CPA (3mg/kg)+Metformin (2mg/kg) treated rats had cognitive deficits 
significantly below that of DMSO/Saline, CPA (3mg/kg)+Metformin (5mg/kg) and CPA 
(3mg/kg)+Metformin (10mg/kg); with CPA (3mg/kg)+Metformin (10mg/kg) producing the 
greatest improvement in spatial memory acquisition and cognitive functioning. Statistical 
testing was performed using One-way ANOVA and Tukey post-test where p<0.05 =*, 
p<0.01=** (Figure 3.4.1 C).  Y-maze testing was typically done in the morning prior to other 













Figure 3.4.2: Metformin treatment at 2mg/kg, 5mg/kg and 10mg/kg appears to alleviate 
CPA-induced anxiety and improves exploratory behaviors.  N=7 individual rats per 
treatment groups – CPA 3mg/kg, CPA+Metformin 2mg/kg, CPA+Metformin 5mg/kg. N=9 
individual rats per treatment groups – DMSO/Saline, CPA+Metformin 10mg/kg.  Extreme 
outliers were excluded from this data set. 
Animals were placed in an open field maze, with an illuminated centre square, which was 
shown to induce anxiety and fear-like behaviors in prey animals leading to a preferential bias 
for frequenting the borders of the field versus the centre square. Animals were left to explore 
this field for 10 minutes, this data was analysed and one-way ANOVA and Tukey post-hoc 
statistical testing was performed.  
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DMSO/Saline and metformin treated animals at 2mg/kg, 5mg/kg and 10mg/kg spent a greater 
amount of time exploring the centre square (Figure 3.4.2 A and B) with an increased number 
of entries (Figure 3.4.2 B) and a greater duration of time spent in this area of the field (Figure 
3.4.2 A), as compared to CPA-treated animals.  
CPA treated animals appeared to frequent the borders of the maze (not shown) and had very 
few entries into the centre square (Figure 3.4.2 A).  
Metformin treatment at 2mg/kg, 5mg/kg and 10mg/kg when given in conjunction with CPA at 
3mg/kg seems to improve locomotion and exploration (Figure 3.4.2 C and D), with animals 
travelling a greater distance overall within the field (Figure 3.4.2 D). Although this difference 
is not statistically significant (p=0.62), a trend is apparent, however, more animals will be 
needed for testing to improve the statistical power of this test. As well as this, the average 
velocity of metformin-treated animals was increased as compared to CPA only treated animals 
which had the lowest overall velocity during the test (Figure 3.4.2 C). Again, this difference 
was not statistically significant (p=0.37), therefore, more animals will be needed for testing to 
improve the statistical power of this test. 
Overall, the open field test revealed that CPA treatment caused increased anxiety and decreased 
mobility and the overall exploration of the field in these animals. However, metformin 
treatment at all three doses appeared to improve both anxiety and locomotion, although this 
result is not yet statistically significant, so no conclusions can be drawn from this test.  
3.4.3 Metformin improves CPA-induced locomotion deficits and depression  
Forced Swim  
Following the Y-maze test (typically performed in the afternoon on the first day of behavior 
testing), a second behavior test was conducted on these animals to investigate the effect of 
adenosine and metformin on motor functioning. While limited in function, we used the forced 
swim test to compare how well the animal was able to swim (success) and how well the animal 
was able to keep its head above water (vigor), and how often the rat was immobile during the 
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Figure 3.4.3.1: Metformin treatment at 10mg/kg showed significant increase in mobility 
during the trial as compared to CPA only treated rats which frequently spent long periods 
of time immobile in the water.  N=10 individual rats per treatment groups – CPA 3mg/kg, 
CPA+Metformin 2mg/kg, CPA+Metformin 5mg/kg. N=12 individual rats per treatment groups 
– DMSO/Saline, CPA+Metformin 10mg/kg. 
The length of time the rats appeared immobile (defined as no movement for at least 3 seconds) 
is positively correlated with depressive behavior, with greater periods of immobility being 
associated with greater levels of depression in animals.  
CPA treatment produced increased % time of immobility (i.e., increased depressive behavior), 
whereas CPA +Metformin treatment at 10mg/kg appeared to attenuate depressive behaviors 
caused by CPA administration. One-way ANOVA statistical testing was performed where 
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Figure 3.4.3.2: Rats treated with Metformin at 2mg/kg, 5mg/kg and 10mg/kg showed 
greater success scores than rats treated with CPA (3mg/kg) alone. N=10 individual rats per 
treatment groups – CPA 3mg/kg, CPA+Metformin 2mg/kg, CPA+Metformin 5mg/kg. N=12 
individual rats per treatment groups – DMSO/Saline, CPA+Metformin 10mg/kg. 
Rats were treated with CPA alone (3mg/kg), CPA and Metformin at 2mg/kg, 5mg/kg and 
10mg/kg or DMSO/Saline once daily for 7 days. Behavior testing was conducted on day 8. 
Animals were placed in a tank filled with water at 25 degrees Celsius and left to swim for 10 
minutes. Success scores were defined as follows: 3-Continuous movement of 4 limbs, 2.5-
Occasional floating, 2-Floating more than swimming, 1.5-Ocassional swimming using 4 limbs, 
1-Ocassional swimming using hind limbs only. 0-No use of limbs. The scores from the first 
three minutes of and the last three minutes of the trial were averaged and analysed using a one 
way-ANOVA test, where p<0.05=*, p<0.01=**, p<0.001=*** and p<0.0001=****.  
Forced Swim testing for motor deficits showed CPA (3mg/kg) rats had the lowest scores for 
success (Figure 3.4.3.2) during the swimming period, when the first three minutes of testing 
were compared with the last three minutes of testing. Metformin treatment at all three doses 
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Figure 3.4.3.3: Rats treated with Metformin at 2mg/kg, 5mg/kg and 10mg/kg showed 
greater vigor scores than rats treated with CPA (3mg/kg) alone. N=10 individual rats per 
treatment groups – CPA 3mg/kg, CPA+Metformin 2mg/kg, CPA+Metformin 5mg/kg. N=12 
individual rats per treatment groups – DMSO/Saline, CPA+Metformin 10mg/kg. 
Rats were treated with CPA alone (3mg/kg), CPA and Metformin at 2mg/kg, 5mg/kg and 
10mg/kg or DMSO/Saline once daily for 7 days. Behavior testing was conducted on day 8. 
Animals were placed in a tank filled with water at 25◦C and left to swim for 10 minutes. Vigor 
scores were defined as follows: 3-Entire head above water, 2.5-Ears but not eyes usually below 
water, 2-Eyes but not nose usually below water, 1.5-Entire head below water for >3 seconds, 
1-Entire head below water for >6 seconds, 0-Animal on bottom of tank for periods of 10 
seconds or longer. The scores from the first three minutes of and the last three minutes of the 
trial were averaged and analysed using a one way-ANOVA test, where p<0.05=* and 
p<0.01=**.   
Forced Swim testing for motor deficits showed CPA (3mg/kg) rats had the lowest scores for 
success (Figure 3.4.3.1) and vigor (Figure 3.4.3.2) during the swimming period, when the first 
three minutes of testing were compared with the last three minutes of testing. Metformin 
treatment at all three doses was able to significantly alleviate CPA-induced motor deficits. 
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With regards to locomotion, we had previously shown in Figures 3.4.2 C and D during open 
field testing, that metformin improved exploratory behaviors and locomotion during open field 
testing. However, this finding was not statistically significant.  On the other hand, with forced 
swim testing we were able to confirm in Figures 3.4.3.1 and 3.4.3.2 that metformin treatment 
was able to improve locomotion. Overall it appears that all doses of metformin were sufficient 
to improve CPA-induced motor deficits, but metformin 10mg/kg was the best dose for the 
improvement of both motor and cognitive functioning of these animals.  
3.5. The effect of metformin during chronic adenosine stimulation on A1R 
expression  
We then conducted Western blotting experiments with biotinylated tissue to assess the effect 
of adenosine receptor expression with metformin following chronic CPA treatment.  
 
Figure 3.5: Metformin treatment appears to prevent the reduction in the expression of 
adenosine A1R in CPA-treated animals. N=4 with 3 individual animal samples per treatment 
group. 
Hippocampal slices were taken from chronically injected animals, biotinylated and 
homogenised over ice with lysis buffer containing protease inhibitors to prevent degradation. 
This tissue was then centrifuged at 15,000g for 5 minutes, and the supernatant was removed 
and stored. Western blotting experiments were then carried out on this tissue with different 
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antibodies at 1:1000 concentrations. Blots were then imaged and analysed using Image J. Data 
was normalised to DMSO/Saline control values which show regular levels of A1R expression 
without the effect of CPA or metformin, and these values were averaged and then compared 
between treatment groups. One-way ANOVA statistical testing was performed, and the 
differences in A1R whole cell protein expression was found to not be statistically significant, 
where p=0.16.   
Data so far suggests that CPA at 3mg/kg causes internalisation of A1R, while metformin 
treatment at all three concentrations (2mg/kg, 5mg/kg and 10mg/kg) restores or prevents the 
internalisation of A1R. However more tissue samples will need to be collected and added to 
this data set before any conclusions can be drawn from this experiment. Future studies will 
investigate whether metformin can also prevent alterations in the surface expression of GluA1 
and GluA2 AMPARs as well as A1Rs and A2ARs.  We will investigate this theory further with 
Western blotting experiments looking at both whole cell and surface receptor expression. 
3.6. Metformin competitive adenosine A1 receptor binding in the presence 
of H3-DPCPX  
Radioligand Binding Assay 
 We conducted a radioligand binding assay using hot-DPCPX and cold metformin on 
hippocampal tissue in collaboration with Dr. Robert Laprairie from the College of Pharmacy 
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Figure 3.6: Metformin displaced adenosine A1 receptor binding by DPCPX.  Metformin 
binds the adenosine A1 receptor with Ki of 48nM. Kd is a measure of the affinity of the 
ligand for its binding site. Since Kd is the concentration at which the ligand binds to half its 
binding sites, IC50 is the concentration of the inhibitor causing 50% inhibition of binding. Ki is 
calculated using IC50 and is defined as the inhibitor constant.   N=8 individual age-matched 
sex-matched hippocampal samples from the same animal litter. 
Hippocampal slices were rapidly frozen in liquid nitrogen, homogenised and centrifuged at 
26500rpm to separate the cell membrane from the intracellular contents. Radioactive DPCPX 
(Perkin Elmer) was then used to competitively bind cold/non-radioactive DPCPX and 
cold/non-radioactive metformin at 6 different concentrations (0.1nM, 1nM, 10nM, 100nM, 
1μM, and 10μM). The overall binding affinity of metformin and DPCPX to A1R was calculate 
in Figure 3.6. 
1nM [H3] DPCPX, 2 h incubation at room temperature, 125 µg protein from rat 
hippocampus. Mean ±SEM, % relative to 100% DPCPX bound. n=8 
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Radioligand binding experiments yielded some interesting results suggesting that metformin 
binds to A1R with a binding constant (Ki) of 48nM, which is somewhat close to the binding 
affinity of adenosine for A1R reported in the literature to be at 70nM approximately. Our 
DPCPX binding studies revealed an affinity of 4.9nM for A1R with the literature reporting a 
value of log 8.4-9.2 which would approximately be between 1nM-10nM.  These results did 
confirm our initial hypothesis concerning metformin A1R-binding but did not provide any 


















Adenosine receptor agonism and antagonism have been implicated in both exacerbating and 
ameliorating disease. As mentioned earlier, the effect of adenosine receptor activation depends 
on the concentration of adenosine present, and the subtype of adenosine receptor that is being 
primarily activated. The effects of A1R activation via CPA, and its potential inactivation via 
metformin, will be compared and contrasted with respect to the studies carried out and the 
results observed. These results will be discussed objectively in relation to the current body of 
literature surrounding the neuroprotective potential of metformin during stroke. 
The effect of metformin on field excitatory post-synaptic potentials 
Initially our findings from electrophysiological studies showed that metformin increases 
hippocampal synaptic transmission, at concentrations greater than 1μM (Figure 3.1 C ). This 
was our first indication that metformin may act to influence A1/A2AR signalling mechanisms, 
as A1R is the most abundant adenosine receptor subtype in the hippocampus and is closely 
followed by adenosine A2AR.  
We hypothesised that metformin could increase neuronal excitability and enhance the 
probability of neurotransmitter release at presynaptic nerve terminals by initially binding to 
A1R as an antagonist like DPCPX.  
In C6 glioma cell lines that underwent hypoxic treatment, researchers found a downregulation 
of A1R and an upregulation of A2AR that was later reversed when A1R antagonist DPCPX 
was used, but not when A2AR antagonist ZM 241385 was used (Castillo, León, Ruiz, 
Albasanz, & Martín, 2008).  Chen et al. (Z. Chen et al., 2014), also observed a downregulation 
of A1R and an upregulation of A2AR  in an in vivo focal cortical ischemia model (using the 
pial vessel disruption or PVD stroke model), which suggests that A2AR expression is 
dependent on A1R activation.  
These earlier studies supported our current findings.  First, consistent with metformin binding 
and inhibiting A1Rs, we found that metformin binding reduces the inhibitory tone on baseline 
synaptic transmission which is normally a reflection of actions of endogenous levels of 
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adenosine on A1Rs.  We observed enhanced fEPSPs in CA1 pyramidal neurons in the 
hippocampus when doses greater than 1μM of metformin were tested for periods of 15 minutes 
or longer.  Second, we observed that metformin prevented the A1R-dependent upregulation of 
A2AR excitatory activity, as the A2AR-dependent hippocampal synaptic potentiation was 
never observed during prolonged normoxic washout.  Third, we found that surface expressed 
A1Rs were downregulated in the presence of the A1R agonist CPA (Z. Chen et al., 2014; Z. 
Chen, Stockwell, & Cayabyab, 2016), and this was largely prevented by metformin.  Fourth, 
behavioral deficits (cognitive dysfunction, depression and anxiety-related behaviors) observed 
after chronic CPA treatments and attributed mainly to the persistent A1R stimulation by CPA, 
were abrogated by metformin, similar to the effects seen with the A1R antagonist DPCPX.  
Finally, based on our observations with high concentrations of metformin at 30μM where there 
was a sudden decrease of fEPSP upon perfusion, we speculated that metformin at such high 
concentrations may be showing non-specific binding to other targets other than adenosine 
receptors. Whether metformin effects at higher concentrations hinders the neuroprotective 
effects observed at lower metformin concentrations, presumably due to actions on other 
molecular and cellular targets, remains to be established. 
The effect of metformin during hypoxic insult 
Now, in relation to the thesis topic at hand which looks to investigate the role of adenosine A1 
receptor action in stroke pathophysiology, we know that A1R activation decreases calcium 
influx (Wu & Saggau, 1997) and supresses the release of excitatory neurotransmitters like 
glutamate (Andiné, Rudolphi, Fredholm, & Hagberg, 1990; Corradetti, Lo Conte, Moroni, 
Passani, & Pepeu, 1984; Fastbom & Fredholm, 1985) acetylcholine (Spignoli, Pedata, & 
Pepeu, 1984) and dopamine (Chowdhury & Fillenz, 1991; Michaelis, Michaelis, & Myers, 
1979). In addition, A1R activation has also been shown to suppress the release of the inhibitory 
neurotransmitter, gamma-aminobutyric acid (GABA) (Hollins & Stone, 1980) (Stone, Ceruti, 
& Abbracchio, 2009). 
When high concentrations of adenosine (10-300μM) were utilised, like those that would be 
found during hypoxic insult, A1R activation appears to have a greater effect in supressing 
glutamate release than in suppressing GABA release to exert its inhibitory effect (Hollins & 
Stone, 1980; Lucchi, Latini, de Mendonça, Sebastião, & Ribeiro, 1996). This preferential bias 
of A1Rs in decreasing glutamate release over GABA when mediating its inhibitory effect is 
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believed to limit the chance for A1R antagonists to cause rebound hyperexcitability (Stone et 
al., 2009), which would result in the increase of seizure-like activity as the inhibition which 
normally would regulate this excitability would have been completely lost.  
This hypothesis although confirmed later by Stone and colleagues (Stone et al., 2009), was 
initially proposed and studied by Von Lubitz and colleagues (D. K. J. E. Von Lubitz, Paul, Ji, 
Carter, & Jacobson, 1994). In their study, chronic A1R antagonist 8-cyclopentyl-1,3-
dipropylxanthine (CPX) treatment eliminated NMDA-induced clonic-tonic seizure episodes, 
increased average survival time and decreased end point mortality after NMDA administration 
but chronic A1R agonist N(6)cyclopentyladenosine (CPA) treatment did not, and rather 
potentiated the NMDA-induced effects.  
On the other hand, acute treatment with CPA resulted in the delay or elimination of seizure 
onset and a significant reduction in mortality, while acute CPX treatment lead to mortality (D. 
K. J. E. Von Lubitz, Paul, Carter, & Jacobson, 1993). 
These studies investigated the effects of acute and chronic A1R agonists and antagonists on 
NMDA-evoked seizures, and found chronic A1R antagonism and acute A1R agonism to be 
neuroprotective and synonymous in nature, thereby alluding to their actions potentially being 
mediated via the same A1R secondary messenger systems (D. K. J. E. Von Lubitz et al., 1994). 
It is known that adenosine elevation during hypoxia results in the activation of adenosine A1R 
receptors, leading to persistent synaptic depression via decreased calcium and glutamate 
release. We proposed that if metformin acts as an A1R antagonist, it should prevent the 
hypoxia-induced synaptic depression like DPCPX does to confer neuroprotection.  
Interestingly, in our experiments we observed a time-dependent neuroprotective effect of 
metformin during hypoxia where metformin at 5μM perfused 5 minutes into hypoxia was not 
neuroprotective but preincubation with the same concentration of metformin prior to the 
induction of hypoxia resulted in significantly reduced cell death as compared with hypoxic 
controls (Figure 3.2.2).  
On the other hand, when we analyzed our electrophysiological data, we saw that metformin 
treatment did not prevent hypoxia-induced synaptic depression as we had initially 
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hypothesized. In fact, there was no significant difference between the synaptic depression 
observed between our control hypoxia treatment, metformin (5μM) when given 5 minutes into 
hypoxia treatment or metformin (5μM) preincubation prior to the induction of hypoxia 
treatment (Figure 3.2.1 C). Nevertheless, we observed metformin (5μM) still induced 
neuroprotection against hypoxia-induced cell death (Figure 3.2.2 C). 
This was an unexpected finding because we believed metformin should have prevented this 
synaptic depression if it mainly acts as an A1R antagonist, but a literature search revealed that 
long term depression (LTD)-inducing stimuli, like hypoxia, or treatments with glutamate 
agonists or treatment with insulin, the antidiabetic agent, all were shown to promote the 
internalisation of AMPARs (Haas, 2001). 
Insulin was shown to mediate AMPAR internalisation via a different mechanism than 
glutamate as insulin treatment caused the internalisation of GluA2, the calcium impermeable 
AMPAR subunit, but not GluA1, the calcium permeable AMPAR subunit. This was due to a 
mechanism that required the last 15 amino acids of the C terminus of GluA2 (Haas, 2001), 
although both mechanisms utilised dynamin-dependent clathrin-coated pits to mediate 
endocytosis. Therefore, our observation indicating that while metformin does not affect the 
A1R-mediated synaptic depression observed during hypoxia (Figure 3.2.1 C), it is possible 
that metformin may be contributing to the internalisation of AMPAR subunits as well as A1Rs 
during hypoxia independent of clathrin-mediated endocytosis. This latter idea regarding 
clathrin-dependent vs. clathrin-independent (or dynamin-independent) endocytosis of surface 
expressed AMPARs and adenosine receptors warrants further investigations.  
Now based on other unpublished observations indicating the important contributions of 
calcium-permeable AMPARs in post-hypoxia synaptic potentiation (submitted Qin et al., 
2019), if metformin is involved in AMPAR internalisation during hypoxia then it may also be 
involved in mediating the post-hypoxia re-insertion of GluA1/A2 AMPA receptor subunits, 
which we now know to be implicated in excitotoxic and pro-apoptotic pathways.  The rapid 
and sustained increase in fEPSP above baseline following normoxic treatment after hypoxia 
was attributed to an adenosine-mediated phenomenon called APSP (adenosine-induced post-
hypoxia synaptic potentiation); whereby adenosine A1 and A2A receptors mediate AMPAR 
trafficking and recycling, causing the reinsertion of the GluA1/A2 AMPA receptor subunits in 
to the cell surface membrane (Z. Chen et al., 2014; Stockwell et al., 2016). 
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(Stockwell et al., 2016) demonstrated that the reinsertion of AMPARs into the cell membrane 
following hypoxia resulted in neurotoxicity which was harmful to hippocampal cell health. 
Their studies showed that preincubation with protein phosphatase inhibitors (Stockwell et al., 
2016) or the utilisation of certain AMPAR antagonists (submitted Qin et al., 2019) was able to 
prevent this AMPAR reinsertion and accompanying synaptic potentiation when administered 
either during hypoxia or post-hypoxia which resulted in significantly lower levels of cell death.  
Therefore, our results suggest that post-hypoxic AMPAR recycling/re-insertion may depend 
on how metformin (5μM) preincubation prior to hypoxia was able to bind to and prevent the 
actions of adenosine A1 and A2A receptors, which are known to modulate the viability of cells 
within the hippocampus even though metformin was unable to prevent the hypoxia-induced 
synaptic depression (Figure 3.2.1 B). 
Our electrophysiological results did in fact reveal that metformin (5μM) preincubation 
prevented the development of APSP while metformin 5μM treatment 5 minutes into hypoxia 
did not prevent APSP (Figure 3.2.1 D).  Given that we know A1R and A2AR activation are 
both implicated in AMPAR recycling, we realised that there must be a time-dependent 
mechanistic change that was occurring at the level of the post-synaptic membrane which 
influences postsynaptic AMPARs (Haas, 2001) and adenosine receptor activity. (Z. Chen et 
al., 2014).  
Qin and colleagues (submitted Qin et al., 2019), also showed that preincubation with antagonist 
of either A1R (DPCPX) or A2AR (SCH58261) prevented the full expression of APSP, and that 
an A1R- and A2AR-dependent insertion of GluA1 and GluA2 AMPAR subunits, may also be 
a potential target of a metformin-A1R-dependent interactions.  
Additionally, it is also important to note the effect of metformin on mitochondrial function as 
it relates to hypoxia. We know from previous studies that mitochondria are very important for 
respiration where they work to generate most of the ATP that the cell requires. Now 
mitochondrial dysfunction on the other hand, has been correlated to a number of 
neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), AD, PD and HD  (Lin 
& Beal, 2006). In these conditions, mitochondrial dysfunction leads to an increase in the 
production of ROS (Lin & Beal, 2006). Under normal physiological conditions, ROS/free 
radicals are rapidly mopped up by oxygen molecules to form water via reactions involving 
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several enzymes present in the mitochondrial space (Lin & Beal, 2006). However under 
pathophysiological conditions this process is disturbed, and these ROS molecules cause 
irreparable damage to the cell leading to apoptosis (Lin & Beal, 2006; Rego & Oliveira, 2003). 
Now, in relation to hypoxia which we know depletes the level of oxygen available to the tissues, 
these free radicals/ROS could not be processed to less harmful compounds such as water. It is 
therefore reasonable to deduce that hypoxic conditions, such as those present in our 
electrophysiology and histology studies (Figure 3.2.1 and 3.2.2 respectively), would 
subsequently trigger increases in ROS levels, causing the cell to favor proapoptotic pathways 
which would augment cell death. 
Several studies within the literature have noted that metformin is able to inhibit complex I of 
the mitochondrial respiratory chain (Viollet et al., 2012). We know that complex I is the first 
of five complexes that make up the respiratory chain, so we believe that by inhibiting the first 
of these complexes, metformin is able to prevent the production of ROS, thereby rescuing 
tissues from ROS-related cell damage, but this concept warrants further investigation.  
Overall, we believe that the disruption of adenosine receptor signalling mechanisms via 
metformin, and potentially its additional role in reducing mitochondrial ROS production are 
involved in mediating its neuroprotective capability to rescue cells from hypoxia-induced cell 
death.  
The effect of metformin on supraphysiological adenosine increase 
CPA is a potent adenosine A1R agonist, therefore we believed it would be a good compound 
to test the idea of metformin A1R antagonism using electrophysiology methods in hippocampal 
brain slices. 
With CPA treatment at 100nM we observed a significant decrease in fEPSP after 10 minutes 
(Figure 3.3.1 B). This finding was expected as earlier studies had shown that a 50nM CPA 
administration for 10 minutes also caused significant levels of synaptic depression with fEPSP 
signalling almost  recovering back to the baseline (Brust et al., 2007). Further studies showed 
that while 50nM CPA was sufficient to induce p38 mitogen-activated protein kinase (MAPK) 
and c-Jun N-terminal kinase (JNK) activation, higher concentrations of CPA with longer 
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incubation times like 500nM CPA for 30-45 minutes also resulted in significant changes in 
surface expression of GluA1 and GluA2 subunits (Z. Chen et al., 2014).   
Now given our hypotheses regarding metformin-A1R binding, we expected that metformin-
treated hippocampal slices would resist CPA-induced synaptic depression, however, we were 
surprised by our results.  When slices were preincubated with metformin (5μM) and then 
treated with CPA at 100nM, rather than observing a prevention in the development of synaptic 
depression, instead we observed the opposite, and saw a greater level of synaptic depression as 
compared to CPA alone (Figure 3.3.1 C). One possibility that could account for this further 
enhancement of synaptic depression observed in the presence of metformin and subsequent 
CPA, is that there may be significant differences in the binding affinity of metformin (see 
below) and CPA (IC50=58nM (Lohse et al., 1988)) to adenosine receptors. That is, it is possible 
that the compound with the higher affinity for A1R (CPA) may be able to displace the lower 
affinity drug (metformin, see below) from binding to A1R.  The higher levels of CPA-induced 
synaptic depression in the presence of metformin could be explained by CPA being able to 
displace metformin from A1R, so that more A1Rs could be occupied by CPA, thereby 
producing increased synaptic depression.  Alternatively, it is plausible that the enhanced 
synaptic depression in the presence of CPA + metformin could also be related to metformin 
binding to and inhibiting A2ARs, thus further inhibiting A2AR-mediated presynaptic 
glutamate release. Hence, future studies are needed to clarify these potential novel effects of 
metformin on adenosine signalling and regulation of synaptic transmission in hippocampus and 
other regions of the brains.  
Additionally, we thought that because there was a greater decrease in fEPSP signalling with 
metformin as compared to CPA 100nM treatment alone (Figure 3.3.1 C) we would also see 
increased propidium iodide fluorescence (i.e., more neuronal death) in this treatment group; 
however again we were surprised because metformin (5μM) treatment decreased the level of 
propidium iodide fluorescence which was indicative of decreased levels of cell death (Figure 
3.3.2 C).  This suggested that metformin’s neuroprotective actions during CPA treatment could 
involve signalling pathways independent of A1R stimulation, that potentially may involve the 
blocking of A2AR which is pro-neurotoxic.  
Now considering the implications of the results from both our acute CPA administration 
experiments (Figures 3.3.1 and 3.3.2) and hypoxia electrophysiological experiments with and 
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without metformin (Figures 3.2.1 and 3.2.2), we believe that metformin may be involved in 
regulating A1R-induced AMPAR internalization by blocking A1R activation and subsequent 
downstream signalling via p38 MAPK, JNK, and PP2A (Brust et al., 2007, 2006; Z. Chen et 
al., 2014). However, it is interesting to note that when electrophysiological effects of metformin 
were examined (Figure 3.3.1 C), we found evidence of synergistic effects of metformin and 
CPA (i.e., greater synaptic depression, consistent with greater A1R stimulation and possibly 
greater subsequent A1R internalization).  This highlights the need to perform additional 
experiments to clarify the acute effects of metformin on CPA-induced synaptic depression.  
However, as discussed below (Figure 3.5), the changes associated with metformin and CPA 
co-administration in our chronic CPA in vivo studies are clear, i.e., metformin appears to 
prevent CPA-induced internalization of A1Rs.  Additional experiments are required to assess 
the effects of metformin on acute (ex vivo slices treatments) or chronic (in vivo drug treatments) 
CPA treatments on A1Rs and AMPARs. 
Furthermore, when we compared the effect of metformin after hypoxia washout, we saw that 
metformin preincubation did also prevent the development of post-hypoxia APSP (Figure 
3.3.1 D). Therefore, taken together we believed that acute application of metformin may indeed 
be implicated in preventing A1R internalization.  Additional studies should not only investigate 
metformin and A2AR binding, but also should address whether metformin also affects the 
subsequent AMPAR insertion to the cell surface after normoxic reperfusion, and whether this 
is the likely mechanism for the reduced cell death revealed in our propidium iodide 
fluorescence studies. 
The effect of metformin on chronic adenosine stimulation 
Considering our current theory concerning metformin potentially regulating AMPAR cycling 
after blocking of A1R binding, we decided to assess the effect of metformin in vivo using 
known potent A1R agonist, CPA. Previous studies, as mentioned earlier, revealed that A1R is 
implicated in regulating A2AR activity and in controlling AMPAR internalization (Z. Chen et 
al., 2014) and reinsertion into the cell membrane (submitted Qin et al., 2019), therefore CPA 
was the drug of choice for utilisation in our in vivo studies. 
CPA is an interesting drug because its acute administration has been shown to exert 
neuroprotective effects during times of cellular stress and/or hyperexcitability and this is a 
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finding that has been noted in the literature in various studies (Melani, Pugliese, & Pedata, 
2014; D. K. J. E. Von Lubitz et al., 1994; Wardas, 2002).  
When investigating the potential effect of CPA administration in vivo, we found in one study 
in particular where researchers contrasted the effect of acute and chronic CPA and CPX 
treatment on spatial memory acquisition in C57BL/6 mice that underwent the Morris water 
maze trials (D. K. Von Lubitz, Paul, Bartus, & Jacobson, 1993). Although the dosing of CPA 
used in these earlier studies was several times lower than what was used in this thesis, it was 
interesting to note that their study found low chronic i.p. doses of CPA at 5μg/kg, 10μg/kg, 
20μg/kg and 30μg/kg over 9 days resulted in a dose-dependent reduction in target latencies, 
rapid spatial preference development and in the absence of animals that were unable to perform 
the task. On the other hand, CPX treatment at 0.2mg/kg, 0.5mg/kg and 1mg/kg resulted in the 
opposite. Interestingly in animals given doses greater than 1mg/kg, locomotor disturbances 
were also apparent (D. K. Von Lubitz et al., 1993). This study was one of the first publications 
to suggest that low dose CPA was able to improve spatial memory formation.  
In contrast, another study noted that the acute stimulation of adenosine A1 receptors via CPA 
at doses ranging from 0.15μmol/kg to 2.25μmol/kg caused a dose-dependent impairment in the 
acquisition and retention of memory during a lick suppression task which measured passive 
avoidance (Normile & Barraco, 1991). These studies highlighted significant differences in the 
effect of CPA at different concentrations and given that adenosine mediates a range of different 
functions, we knew that it was very important to find the limit of the therapeutic window for 
CPA dosing that we could safely utilise to induce neurotoxic cerebral effects without inducing 
other deleterious systemic effects.  
Fortunately, a follow-up supporting study by (D. K. Von Lubitz et al., 1994) looked into the 
effect of acute (i.p. 15 minutes prior), chronic (i.p. 15 days prior), low-dose (0.02mg/kg) and 
high-dose (1mg/kg) CPA and CPX treatment on ischemic damage and survival after occlusion 
of the carotid arteries. These researchers found significant differences in their results which 
became the backbone for the interpretation of our data in the in vivo study. 
Acute CPA treatment at 0.02mg/kg or 1mg/kg, significantly improved survival rate (94% and 
90% respectively) and neuronal preservation in comparison to vehicle-controls (60%). While 
on the other hand, chronic CPA treatment at 0.02mg/kg resulted in no significant difference in 
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survival rate (74%) and neuronal preservation, and 1mg/kg chronic CPA treatment resulted in 
a significantly lower survival rate (14%), and fewer surviving neurons (D. K. Von Lubitz et 
al., 1994). Acute CPX treatment at 1mg/kg also resulted in significantly lower survival rates 
(20%) and decreased neuronal survival, while chronic CPX treatment at 1mg/kg resulted in 
increased survival rate (93%) and greater neuronal preservation. 
Taken together these studies highlight that the duration and dose of A1R agonist and antagonist 
administration are equally important in modulating hippocampal damage, spatial memory 
formation, and survival rates after ischemia, contributing to the idea of ischemic 
preconditioning (Dunwiddie & Masino, 2001). To elaborate, acute A1R stimulation, or low 
dose chronic A1R stimulation is thought to confer neuroprotection against pathological events 
by increasing the inhibitory effect of A1R. However, there is also data suggesting that A1R 
agonists when given chronically at high doses are neurotoxic as they cause the internalisation 
of A1R and thus the loss of the A1R-mediated inhibitory neuroprotective effect that other 
studies had been reporting earlier. It appeared that concentrations of CPA greater than 1mg/kg 
were neurotoxic when administered chronically (D. K. Von Lubitz et al., 1994) or greater than 
5mg/kg when administered acutely (Stockwell et al., 2017).  
Consequently, in our study we had chosen to utilise 3mg/kg of CPA to be injected once daily 
over 7 days, to facilitate the CPA-induced neurotoxic effects that we hoped metformin would 
counteract as a proposed A1R antagonist. We realised that if metformin was able to prevent 
CPA-induced behavioral deficits and effects then there would be sufficient experimental 
evidence to suggest not only metformin-A1R binding but direct A1R antagonism as well. 
The effect of metformin on learning circuits 
With CPA at 3mg/kg treatment, we observed significant impairments in hippocampal-
dependent spatial memory and learning during Y-maze testing which we attributed to be caused 
by A1R-mediated neurotoxic pathways. CPA treatment also caused significant damage to 
hippocampal neural circuits and augmented cell death in DG and CA1-3 areas but metformin 
treatment at 10mg/kg was able to significantly reverse this damage (data not shown) and restore 
cognitive function (Figure 3.4.1).   
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We know that CPA causes the internalisation of A1Rs (Z. Chen et al., 2014), and the loss of 
A1R has also been implicated in AD pathology and in dementia studies (Kalaria, Sromek, 
Wilcox, & Unnerstall, 1990). Radioactive DPCPX, a high affinity A1R antagonist, was used 
in another study to confirm or dispute the suggestion of A1Rs loss within the hippocampus 
being implicated in AD pathology and dementia (Deckert et al., 1998). This seemed to be a 
logical hypothesis to test given that there are large numbers of adenosine receptors in the 
hippocampus which is the centre for learning and memory. However, their study found A1R 
loss to also be implicated in several other pathologies and concluded that A1R loss was not 
specific to AD pathology (Deckert et al., 1998). Interestingly A1R knockout models did not 
show deficits in spatial memory formation (Giménez-Llort et al., 2005) suggesting that there 
may be compensatory mechanisms involved in hippocampal dependent memory/learning 
circuits that are independent of A1R. 
Interestingly with low concentrations of metformin (2mg/kg), CPA administration had an 
increasingly negative effect on hippocampal spatial memory formation (Figure 3.4.1). One 
explanation for the reason behind this increased deficit goes back to the idea of adenosine 
agonism versus antagonism having contrasting effects; and given that the dose of metformin is 
less than the dose of CPA, we believed that it was not enough to counteract the CPA-induced 
cognitive deficits. 
Within this same treatment group we also noted an increase in the proportion of time these 
animals spent not moving within, or frequently returning to the start arm of the Y-maze, versus 
the time they spent exploring the novel arm which could be indicative of anxiety (Montgomery, 
1955). To further investigate this result, we performed the open field test.  
The effect of metformin on anxiety behaviors 
While all animals in our study showed a preferential bias for the borders of the maze, CPA-
treated animals had the fewest number of entries into the centre of the field (Figure 3.4.2 B). 
They also frequently exhibited freezing behavior throughout the trial and had the slowest 
overall velocity (Figure 3.4.2 C). On the other hand, metformin-treated animals at all 
concentrations explored the maze and showed an approximately equal increase in the number 
of entries into and time spent in the centre square over CPA-treated animals (Figure 3.4.2 B 
and 3.4.2 A respectively). Similarly, A1R-knockout mice also showed reductions in 
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exploratory behavior in the open field test, and increased anxiety in the plus maze and dark-
light box (Giménez-Llort et al., 2002). 
It was also noted by Giménez -Llort and colleagues (Giménez-Llort et al., 2002), that A1R-
knockout mice exhibited reduced muscle strength. Therefore, given that our open field test 
results had revealed that CPA-treated animals had lower velocities (Figure 3.4.2 C), travelled 
less (Figure 3.4.2 D) and spent a larger proportion of their exploration time immobile in the 
field, as well as the fact that we knew CPX-treatment at 1mg/kg caused locomotor changes (D. 
K. Von Lubitz et al., 1993), we decided to utilise the forced swim test to investigate whether 
CPA treatment at 3mg/kg caused motor changes and/or deficits. 
The effect of metformin on depressive behaviors 
The forced swim test revealed less successful (Figure 3.4.3.2) and vigorous (Figure 3.4.3.3) 
swimming in CPA-treated animals as compared to controls. These animals failed to keep their 
heads above the water during the trial, often did not utilise all their limbs to improve swimming 
ability and spent large periods of time immobile in water. This could be due to CPA-mediated 
changes in the basal ganglia direct pathway or it could be due to an increase in fear and 
depressive behaviors which would also cause these same effects. Further experiments like the 
sucrose-preference test or even the imaging of dopaminergic neuronal pathways would be a 
great way to assess this result. 
Interestingly, all concentrations of metformin improved CPA-induced motor deficits. 
Metformin-treated animals spent most of their time mobile in water, dived frequently within 
the tank and swam successfully throughout the trial. Earlier in this thesis it was mentioned that 
metformin treatment at 2mg/kg was not sufficient to ameliorate the CPA-induced learning 
deficit that was observed during Y-maze testing (Figure 3.4.3.1). This dose of metformin in 
combination with CPA at 3mg/kg was shown to result in poorer cognition and an increase in 
anxiety-like behavior. However, during the forced swim test within this same treatment group 
we observed significant improvements in CPA-mediated depressive behavior which was an 
unexpected finding given the previous Y-maze testing result. This led us to question whether 
depressive circuits were less sensitive to stress and injury than hippocampal learning circuits. 
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A study by Snyder and colleagues (Snyder, Soumier, Brewer, Pickel, & Cameron, 2011) 
showed that the inhibition of neurogenesis in the hippocampi of adult mice increased despair-
like behaviors. Therefore given that several studies have confirmed the ability of metformin to 
induce neurogenesis in the brain (Ghadernezhad et al., 2016; Liu, Tang, Zhang, et al., 2014; 
Patil, Jain, Ghumatkar, Tambe, & Sathaye, 2014; J. Wang et al., 2012), it is very possible that 
the dose of metformin utilised was too low to be beneficial in improving CPA-induced memory 
deficits, and that this was the reasoning behind that result. Indeed, this finding may highlight a 
novel mechanism in the pathway to understanding metformin-adenosine interactions, but other 
experiments are needed, and this may be a future direction for this study.   
Taken together, our behavioral experiments revealed that 10mg/kg of metformin co-
administered with CPA 3mg/kg was the most effective dose in vivo in conferring 
neuroprotection against CPA-induced cognitive and locomotor deficits. Metformin at this dose 
also improved hippocampal cell health and prevented the development of anxiety and 
depressive behaviors.  
Metformin binding to adenosine receptors 
Another important finding in our study was verifying the novel interaction for metformin 
binding to A1R. Western blotting studies confirmed earlier results by Chen et al. (Z. Chen et 
al., 2014) suggesting that prolonged A1R stimulation via CPA administration causes the 
internalization of A1R. Our results also showed that metformin treatment at all three 
concentrations appeared to prevent this internalization (not shown), although this difference 
was not statistically significant. Additionally, radioligand binding studies using H3-DPCPX 
revealed that metformin binds to A1R with an affinity of 48nM, making it an A1R ligand. To 
compare the binding affinity of metformin with other A1R ligands to know its relative potency, 
we utilised non-radioactive DPCPX as our control which revealed a 4.9nM binding affinity for 
A1R (Figure 3.6). However, radioligand binding could be utilised with other A1R agonists 
and antagonists like 2-Chloro-N6-cyclopentyladenosine (CCPA), or rolofylline (KW 3902) 
(Kenneth A Jacobson & Gao, 2006) to better characterise the metformin-A1R binding profile.  
While radioligand binding studies reveal a novel metformin-A1R binding interaction, which is 
supported by our previous experiments both ex vivo and in vivo, we have to note that we did 
also observe an A2AR antagonist-like response during our hypoxia electrophysiology studies 
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(Figure 3.2.1 B). This means that we cannot rule out the possibility that metformin has non-
specific adenosine receptor binding potential, which it utilises to mediate its neuroprotective 
effect. We know from the literature that adenosine receptors have been shown to interact with 
other adenosine receptors to form heteromers (Ciruela et al., 2006), and the same observation 
has also been noted with dopamine receptors (Fuxe, Ferré, Genedani, Franco, & Agnati, 2007). 
Therefore, there is also a possibility that metformin may bind A1R specifically but mediate the 
A2A receptor response via this mechanism. 
All these ideas and concepts are significant to unravelling the mystery behind the role of 
metformin in improving T2D/stroke patient outcome because it would explain why a number 
of T2D sufferers treated with long-term metformin have lower rates of PD (Wahlqvist et al., 
2012) and stroke (Cheng et al., 2014). Although with regards to metformin and AD, there is 
some controversy as to whether metformin ameliorates or exacerbates the condition (Imfeld, 
Bodmer, Jick, & Meier, 2012; Yarchoan & Arnold, 2014). On the other hand, in pathologies 
where we know A1R is implicated in the development of the disorder, utilising metformin 
could yield significant therapeutic benefits.  
5. LIMITATIONS  
Some limitations of our study were that we used ex vivo hypoxia treatment as an alternative 
means of reproducing some responses to an ischemic stroke on hippocampal brain slices. Not 
only did we change the environmental conditions of the brain during the decapitation and 
slicing procedure but we also could not mirror the pathophysiology of stroke using hypoxia. 
Another limitation of the study was that we did not utilise an in vivo stroke model to confirm 
our findings, as chronic A1R stimulation via i.p. injections also would not mimic pathological 
stroke conditions. Another limitation of the study is that we did not utilise other radioactive 
and non-radioactive adenosine A1R ligands to compare and contrast metformin A1R-binding 
affinity with other ligands. It would have been interesting to test the effect of metformin 
administration on blood glucose levels to determine if any of our observed metformin-
associated behavioral improvements involved changes in blood glucose levels.  In addition, 
further tests with metformin administration alone in vivo, a potential confound in this study, 




We started this study with three objectives: to understand the effect of varying concentrations 
of CPA in vivo and ex vivo, to characterise the effects of metformin on hippocampal health 
after exposure to chronic A1R signalling, and to investigate the effect of metformin on 
adenosine A1R signalling in vivo and ex vivo. Our results showed that hypoxia-induced cell 
death was in part due to adenosine A1R activation. We know this because A1R agonist CPA 
(100nM) administration produced similar levels of cell death. We found that whether CPA was 
administered acutely ex vivo or chronically in vivo it was neurotoxic and augmented cell death. 
Metformin on the other hand increased fEPSP signalling and conferred neuroprotection both 
ex vivo and in vivo during hypoxia and during CPA treatment, respectively. These studies 
highlighted a potential novel role of metformin during stroke as metformin was able to prevent 
CPA-induced A1R internalisation upon acute and chronic adenosine stimulation. Therefore, 
during sustained adenosine release, which normally would be considered neurotoxic, we found 
metformin was able to prevent both hypoxia-induced cell death, and adenosine-mediated cell 
death. We attributed this effect to metformin’s ability to bind to and antagonize A1Rs, as we 
found metformin was indeed able to bind to and displace a prototypical A1R antagonist 
(DPCPX) with an apparent binding affinity of 48nM. Therefore, we believe that metformin 
acts an A1R antagonist like DPCPX but may also have binding affinities for other adenosine 
receptors, and that by primarily blocking A1Rs at times where this receptor would be prone to 
exerting its neurotoxic effects, metformin was able to confer neuroprotection.  
7. FUTURE DIRECTIONS 
It is imperative that we investigate the potential of metformin to bind to other adenosine 
receptors like A2A, A2B, and A3 with radioligand experiments. Already in our experiments so 
far, we have seen metformin exert A2AR antagonist-like effects, including 1) prevention of the 
A2AR-dependent synaptic potentiation during prolonged normoxic washout following a 20 
min hypoxic stimulation, 2) lack of effect on maximal fEPSP inhibition during hypoxia-
induced synaptic depression, and 3) relatively low affinity of metformin on A1R binding. This 
is of note, particularly because A2AR is a receptor of interest in diseases like PD and epilepsy. 
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Metformin is already clinically approved for T2D, but we believe it could be repurposed for 
other diseases, and conditions involving adenosine receptors given that we have shown 
metformin is able to improve motor deficits, reduce post-hypoxic excitability and improve 
cognition.  
Future experiments would also involve characterising signalling molecules of note involved in 
mediating adenosine receptor pathways (AMPK, PP2A, MAPK, JNK) to better understand 
how metformin is able to attenuate neurological disease pathogenesis. 
It is also our hope to administer metformin following pial vessel disruption (PVD) surgery to 
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